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Cardiomyopathies are heart diseases, which are categorized according to morphology 
and function into hypertrophic, dilated, restrictive and arrhythmogenic right ventricular 
subtypes with significant genetic and phenotypic overlap. Dilated cardiomyopathy (DCM) 
is a heart disease characterized by left ventricular dilatation and systolic dysfunction in the 
absence of abnormal loading conditions or coronary artery disease sufficient to cause the 
phenotype. The diagnosis is based on echocardiography or other imaging modalities. The 
prevalence of DCM is estimated to be at least 1:2500. The proportion of familial or genetic 
DCM is currently estimated to be 30-50%. The mode of inheritance is typically autosomal 
dominant, but also recessive, X-linked, and mitochondrial inheritance patterns have been 
identified. Truncating titin variants, i.e. mutations leading to a truncated form of the 
protein, are the most common genetic cause of DCM.  However, over 40 genes have been 
related to DCM, and about a hundred to cardiomyopathies in general, which is why the 
genetic etiology has often remained unknown even in familial cases using traditional 
Sanger sequencing.  
Next generation sequencing methods allow the sequencing of all known 
cardiomyopathy-related genes simultaneously. As a result many DCM patients without a 
genetic diagnosis are receiving one. On the other hand more and more patients are found 
to carry a variant of unknown significance (VUS), a rare genetic variant, which could be 
disease causing, insignificant, or possibly a modifying variant. Even with modern 
sequencing methods thorough variant classification is as important as ever, relying on 
disease co-segregation with the variant combined with several other factors. Dilated 
cardiomyopathy is not a homogeneous disease entity, and some genetic causes produce a 
distinct phenotype. These genotype-phenotype correlations can help to identify familial 
disease, lead to successful genetic testing and guide clinical decision-making. In clinical 
practice genotype information still quite rarely affects treatment. As genotype-phenotype 
information accumulates it is likely that the management of dilated cardiomyopathy 
becomes more individualized taking the genotype in account.  
The aims of this thesis were the identification of new cardiomyopathy-causing variants, 
and the description of genotype-phenotype correlations in dilated cardiomyopathy.  
LMNA mutations are the second most common cause of genetic dilated 
cardiomyopathy. In this thesis new LMNA mutations were reported, and LMNA mutation 
carriers were studied in detail to further analyse the phenotype. 
In study I four cardiomyopathy-causing LMNA variants were identified. One of the 
mutations was studied in more detail due to its atypical phenotype affecting primarily the 
right side of the heart. In study II 26 individuals carrying DCM-causing LMNA-mutations 
were studied repeatedly using spiroergometry. The symptomatic mutation carriers showed 
a lower maximal working capacity, maximal oxygen uptake and fraction of end-tidal CO2 
(FetCO2), and an increased slope of ventilation/carbon dioxide exhaled, or VE/VCO2 slope 
during exercise, namely, changes seen typically in heart failure patients. The findings of 
  4 
the asymptomatic mutation carriers concerning maximal working capacity and oxygen 
uptake were similar to those of healthy controls. However, the asymptomatic mutation 
carriers had higher VE/VCO2 slope and lower FetCO2 levels than the healthy controls 
suggesting inefficient ventilation during incremental exercise. The results in study II 
suggest that signs of inefficient ventilation during exercise might imply evolving 
cardiomyopathy in LMNA mutation carriers.  
In study III clinical follow-up results of 27 LMNA mutation carriers were reported and 
a new ECG entity common in LMNA mutation carriers and rare in other cardiomyopathy 
patients was introduced. In the clinical follow-up men exhibited cardiomyopathy 
symptoms earlier than females. Due to rigorous follow-up a very high non-sustained 
ventricular tachycardia (NSVT) prevalence, 77.8%, was found in LMNA mutation carriers 
highlighting the need for accurate risk-assessment schemes for clinical decision-making 
concerning ICD implantation. Septal remodeling, i.e. ECG abnormalities present in 
standard ECG leads V1-V3 were very common in LMNA mutation carriers, quite rare in 
DCM patients without LMNA mutations and absent in healthy controls. This suggests that 
septal pathology is typical to cardiolaminopathy.  
In study IV a targeted sequencing panel using Os-Seq technology and covering 101 
genes associated with cardiomyopathy was used to study 145 Finnish DCM patients. Study 
IV confirmed the significance of truncating titin variants as the most significant known 
cause for DCM. Truncating titin variants were found in 20.6% of familial DCM patients 
and 14.6% of non-familial DCM patients. The overall diagnostic yields were 47.6% for 
patients with familial disease and 25.6% for those without a family history of 
cardiomyopathy. Among other findings a likely Finnish founder mutation DSP c.6310delA 
p.(Thr2104Glnfs*12) was found in 6 non-related probands. Study IV also showed that a 
panel-based next generation sequencing approach is useful in the genetic diagnostics of 
cardiomyopathy. 
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Kardiomyopatiat eli sydänlihassairaudet jaotellaan morfologian perusteella ja 
toiminnallisesti hypertrofiseen, dilatoivaan, restriktiiviseen, oikean kammion 
arytmogeeniseen ja luokittelematomiin kardiomyopatioihin. Kardiomyopatioiden 
ilmiasuissa ja genetiikassa on kuitenkin merkittävää päällekkäisyyttä. Dilatoivassa 
kardiomyopatiassa (DCM) sydämen vasen kammio laajentuu ja sen pumppausteho 
heikkenee. Diagnoosi perustuu sydämen ultraäänitutkimukseen tai muuhun 
kuvantamismenetelmään, kuten sydämen magneettikuvaukseen. Muut samankaltaiseen 
ilmiasuun johtavat tilat tulee sulkea pois ennen diagnoosin asettamista. DCM:n 
esiintyvyydeksi arvioidaan vähintään 1:2500, ja suvuttaisen taudin osuudeksi 30-50%. 
Tyypillisin periytymismalli on autosomaalinen dominantti, mutta myös resessiivinen, X-
kromosomaalinen ja mitokondriaalinen periytymistapa ovat mahdollisia. Trunkoivat, eli 
tynkäproteiinin muodostukseen johtavat, titiinimutaatiot (TTNtv) ovat yleisin DCM:n 
geneettinen syy. Muita DCM-tautigeenejä tunnetaan yli 40, ja kardiomyopatiaan yleisesti 
liitettyjä geenejä noin sata, mistä johtuen DCM:n genetiikan tutkiminen on ollut työlästä 
perinteisillä menetelmillä.   
Uuden polven sekvensointimenetelmät (NGS, next generation sequencing) 
mahdollistavat kaikkien kardiomyopatioihin liitettyjen geenien samanaikaisen 
sekvensoinnin. Menetelmien kehityksestä johtuen yhä useammat DCM-potilaat voivat 
saada tarkan geneettisen diagnoosin kliinisen diagnoosin lisäksi. Toisaalta myös 
epäselvien varianttien (VUS, variant of unknown significance) määrä lisääntyy. Tämän 
vuoksi tarkka varianttianalyysi, joka perustuu kosegregaation arvioimiseen ja muihin 
kriteereihin, on tärkeää. DCM:n kliininen kuva on vaihteleva, ja jotkut geenivirheet 
aiheuttavat tyypillisen, muista eroavan ilmiasun. Genotyyppi-fenotyyppi-analyysistä 
saattaakin olla hyötyä (suvuttaisen) sairauden tunnistamisessa sekä yksilöllisissä 
hoitoratkaisuissa. Käytännössä genotyypin mukaan räätälöity hoito ei ole vielä arkipäivää, 
vaan mahdollistunee genoyyppi-fenotyyppi-tiedon lisääntyessä tulevaisuudessa. 
Tämän tutkimuksen tavoitteena oli tunnistaa uusia kardiomyopatiaa aiheuttavia 
geenivirheitä sekä kuvata niitä mahdollisimman tarkasti. Osatyöt I-III käsittelivät LMNA-
geenivirheitä ja niiden kliinistä kuvaa. Osatyössä I kuvattiin neljä LMNA-mutaatiota, joista 
yhtä tarkasteltiin tarkemmin, sillä sen ilmiasu oli tavallisesta poikkeava. Kyseisen 
mutaation kantajilla kardiomyopatia affisioi erityisesti sydämen oikeaa puolta. Osatyössä 
II tutkittiin 26 LMNA-mutaationkantajaa toistetuilla spiroergometriatutkimuksilla. 
Oireisten mutaationkantajien spiroergometrialöydökset olivat sydämen vajaatoimintaan 
sopivia; kokonaissuorituskyky, maksimi hapenkulutus ja uloshengitysilman 
hiilidioksidipitoisuus loppu-uloshengityksessä (FetCO2) olivat alentuneet, kun taas 
minuuttiventilaation ja hiilidioksidintuotannon suhteen kulmakerroin (VE/VCO2 slope) 
oli koholla. Oireettomien mutaationkantajien tulokset olivat samankaltaisia kuin terveiden 
verrokeiden, mutta heilläkin VE/VCO2 käyrän kaltevuus oli koholla ja FetCO2 oli 
alentunut viitaten epätaloudelliseen ventilaatioon rasituksen aikana. Rasituksenaikainen 
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ventilaation epätaloudellisuus saattaakin olla merkki subkliinisestä kardiomyopatiasta. 
Osastyössä III raportoitiin 27 LMNA-mutaationkantajan kliinisen seurannan tuloksia. 
Päälöydöksinä oli, että LMNA-mutaation aiheuttamat sydänpoikkeavuudet ilmaantuvat 
aikaisemmin miehille kuin naisille. Lisäksi havaittiin, että lyhyet 
kammiotakykardiapyrähdykset (NSVT) ovat hyvin yleisiä LMNA-mutaationkantajilla. 
Tämän vuoksi vakavien kammiotakykardioiden ilmaantumisriskin arvioimista tulee 
kehittää näillä potilailla, jotta ennaltaehkäisevät rytmihäiriötahdistimet osataan kohdistaa 
potilaille, jotka niistä hyötyvät. Osatyössä raportoitiin myös EKG-poikkeavuus, englanniksi 
“septal remodeling”, joka on yleinen LMNA-mutaationkantajilla, mutta harvinainen DCM-
potilailla, joilla ei ole LMNA-mutaatiota. Kyseinen EKG-poikkeavuus viitannee paikallisiin 
poikkeavuuksiin septumissa.  
Osatyössä IV tutkittiin 145 suomalaista DCM-potilasta NGS-teknologiaa hyödyntävällä 
Os-Seq-menetelmällä, joka kattoi 101 kardiomyopatioihin liitettyä geeniä. Tutkimus 
vahvisti trunkoivien titiinimutaatioiden merkityksen DCM:ssä; familiaalisessa DCM:ssä 
20,6%:lta löytyi TTNtv ja sporadisessakin 14,6%:lta. Kaiken kaikkiaan todennäköisen 
geenidiagnoosin sai 47,6% familiaalista ja 25,6% sporadista tautia sairastavista. Muista 
löydöksistä merkittävin oli DSP c.6310delA p.(Thr2104Glnfs*12) variantti, joka löytyi 
kuudelta DCM-indeksihenkilöltä, jotka eivät olleet sukua toisilleen. Tutkimus osoitti myös 
Os-Seq-menetelmän käyttökelpoisuuden kardiomyopatioiden geenidiagnostiikassa.  
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AF  allele frequency 
AFib  atrial fibrillation 
AHA   American Heart Association 
AMPK adenosine monophosphate-activated kinase 
ARVC arrhythmogenic right ventricular cardiomyopathy 
AV block atrioventricular block 
CMR  cardiac magnetic resonance imaging 
CPET cardiopulmonary exercise testing 
CRT  cardiac resynchronization therapy 
CRT-D cardiac resynchronization therapy defibrillator 
DCM  dilated cardiomyopathy 
DNA  deoxyribonucleic acid 
DSC2  desmocollin-2 gene 
DSG2 desmoglein-2 gene 
DSP   desmoplakin gene 
ECG  electrocardiogram 
ESC  European Society of Cardiology 
ESP  NHLBI Exome Sequencing Project  
ExAC Exome Aggregation Consortium 
??????? ?????????????????????????? 
FS  fractional shortening 
gnomAD Genome Aggregation Database 
HCM  hypertrophic cardiomyopathy 
HGMD Human Gene Mutation Database 
ICD  implantable cardioverter-defibrillator 
iPS cell induced pluripotent stem cell 
JUP  plakoglobin gene 
LMNA LMNA gene 
LOD  logarithm of odds 
LVEDD left ventricular end-diastolic diameter 
LVEF left ventricular ejection fraction 
LVH  left ventricular hypertrophy 
MYBPC3 myosin-binding protein C gene 
MYPN  myopalladin gene 
MYH6 alpha-myosin heavy chain gene 
MYH7 beta-myosin heavy chain gene 
NGS  next-generation sequencing 
NHLBI  National Heart, Lung, and Blood Institute 
NSVT non-sustained ventricular tachycardia 
NYHA New York Heart Association 
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Os-Seq oligonucleotide-selective sequencing 
PCR  polymerase chain reaction 
PKP2  PKP2 gene 
PRKAG2 protein kinase AMP-activated non-catalytic subunit gamma 2 gene 
PSI  proportion spliced in 
RBM20 RNA binding motif protein 20 gene 
RCM  restrictive cardiomyopathy 
RQ  respiratory quotient (VCO2/VO2) 
SCD  sudden cardiac death 
SCN5A sodium voltage-gated channel alpha subunit 5 gene 
SD  standard deviation 
SiSu  Sequencing Initiative Suomi 
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TGFβ3 transforming growth factor-β3 gene 
TMEM3 transmembrane protein 3 gene 
TNNT2 cardiac troponin T type 2 gene 
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The term cardiomyopathy was first introduced in mid-1900s. Due to the variable 
phenotypes, evolving diagnostics, and understanding of etiology, multiple classification 
systems have been proposed over the years. (1) The 1980 World Health Organization 
(WHO) Task Force defined cardiomyopathies as “heart muscle diseases of unknown cause” 
highlighting the then limited understanding of etiology, and divided cardiomyopathies 
according to morphology and histology into dilated (DCM), hypertrophic (HCM) and 
restrictive (RCM) subtypes. (2) The 1995 version introduced arrhythmogenic right 
ventricular cardiomyopathy (ARVC) as a distinct cardiomyopathy subtype. (3) The most 
recent classification systems are the American Heart Association (AHA) classification from 
2006 and European Society of Cardiology (ESC) working group statement from 2008. (1, 
4) Both statements aimed to fuse the traditional classification to the advances made in 
understanding etiology, especially genetics.  
The 2008 European Society of Cardiology working group statement defines 
cardiomyopathies as myocardial disorders with structural and functional abnormalities in 
the absence of coronary artery disease, hypertension, valvular disease, or congenital heart 
disease sufficient to cause the phenotype in question. Furthermore, cardiomyopathies are 
divided into familial and non-familial forms; familial meaning that the phenotype or a 
phenotype possibly caused by the same gene defect is present in a family member. Figure 
1a shows the basis of this classification system. The working group statement continues to 
divide non-familial cardiomyopathy to idiopathic, in which the cause is unknown, and 
acquired, in which the cardiac phenotype is a complication of a known disorder, such as 
amyloidosis or myocarditis. Familial, on the other hand, is divided into subtypes based on 
the genetic cause and whether it is known. (4) The AHA classification takes a slightly 
different approach by first making the division into primary and secondary 
cardiomyopathy, primary affecting only the heart, and secondary being a part of a systemic 
disease with myocardial involvement. (1) Figure 1b presents a schematic interpretation of 
the 2006 AHA classification. One of the main differences in the European and American 
classification systems is the inclusion of channelopathies in the AHA classification (1), and 
the purposeful exclusion of them in the ESC classification. (4, 5) The division into primary 
and secondary cardiomyopathies in the AHA classification can be criticized as somewhat 
arbitrary as, for instance, many genetic muscular syndromes include cardiac 
manifestations, and conversely many genetic cardiomyopathies have extra-cardiac 
manifestations. (6-9) Also the division into genetic, mixed and acquired is a bit 
problematic, and the allocation of cardiomyopathies into these subtypes is in some cases 
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already out-dated. For instance, peripartum cardiomyopathy is listed as an acquired 
condition, but it has later been showed that gene variants causing DCM may also 
predispose to peripartum cardiomyopathy. (10) It can also be questioned why genetics 
wasn’t more strongly incorporated into these classification systems. A feasible reason for 
this is that most cardiomyopathy patients are still recognised based on phenotype as 
opposed to genotype. (5) However, this is already changing as more and more family 
members of cardiomyopathy patients are identified based on genotype. The rapid 
development of genetic variant classification and recognition of disease-causing genetic 
variants will likely affect the next propositions for cardiomyopathy classification systems.  
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Dilated cardiomyopathy is defined as left ventricular dilatation and left ventricular systolic 
dysfunction in the absence of abnormal loading conditions or coronary artery disease 
sufficient to cause the phenotype. (4) Traditionally, the diagnosis has been based on 
echocardiography, but cardiac magnetic resonance imaging (CMR) is an emerging 
diagnostic entity. (11) Neither the ESC nor the AHA classification systems define 
specifically the level of dilatation or systolic dysfunction required for diagnosis, and 
variation exists in the criteria used. Mestroni et al. suggested left ventricular ejection 
fraction (LVEF) <45% and/or fractional shortening (FS)<25%, both corresponding to >2 
standard deviations (SD) and left ventricular end-diastolic diameter (LVEDD) >117% of 
the predicted value corrected for age and body surface area corresponding to >2 SD of the 
predicted normal limit +5%. (12) These were an adaptation from the Manolio criteria (13) 
from 1992 with a slightly different criterion for LVEDD, >27 mm/m2,  criticized for worse 
specificity. (12) However, in clinical and research practices looser criteria are often used, 
sometimes with specific limits given only for LVEF. (14, 15) The Mestroni et al. (12) 
recommendation also lists exclusion criteria, which can cause a similar phenotype; 
systemic arterial hypertension with specific limits, coronary artery disease with >50% 
obstruction in a major branch, history of chronic excessive use of alcohol, again with 
specific limits, clinical sustained and rapid supraventricular arrhythmias, systemic 
diseases, pericardial diseases, congenital heart disease, and cor pulmonale. (12) 
The prevalence of dilated cardiomyopathy has previously been estimated to 1:2500-
3000 (12, 16), however these figures are based on rather old data, and it is now accepted 
that the prevalence is likely much higher, (17) estimated even up to 1:250.(18) This revised 
prevalence estimate is important when evaluating the frequencies of DCM-associated 
variants in population studies or reference populations. However, one should remember 
that the figure 1:250 is not obtained from a population-based study. Instead, it is a rough 
revised estimate based on the fact that the hallmark Olmstead county prevalence study 
from 1989 (16) underestimated the prevalence of HCM ten-fold, and might, thus, have 
similarly underestimated the prevalence of DCM.(18) As there is a lack of up-to-date large-
scale population-based studies on the prevalence of DCM it is particularly difficult to 
compare the prevalence numbers between different populations. A Japanese study from 
2002 reported an estimated prevalence of 1:7000 for DCM in Japan (19) while an English 
study from 1985 reported a prevalence of 1:12 000. (20) Since these studies are from an 
era when the availability of cardiac imaging was very different from today, it is difficult to 
draw conclusions from them, and newer population-based studies from different 
ethnicities are needed.   
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The ESC Working group on myocardial and pericardial diseases has given a structured 
recommendation on the diagnostic process in cardiomyopathies. (11) The recommendation 
describes an approach based on detailed personal and family history, continued with 
thorough clinical assessment and combined with targeted molecular genetic testing in 
select cases.  It emphasizes the significance of each step with the idea that information 
gathered should direct further assessment, and the aim should be a specific diagnosis, as it 
can influence the management of the individual patient as well as family members.
The assessment should begin with the exclusion of common causes for ventricular 
dysfunction, such as hypertension, myocardial ischemia, valve dysfunction, and prior 
exposure to toxins. The detailed personal history should include general medical history as 
well as cardiac, bearing in mind the possibility of multisystem, syndromic, neuromuscular, 
or metabolic disease. (1, 4, 11) Family history ought to be covered in a systematic way using 
a three- or four-generation pedigree as a tool. Additionally to cardiac disease, signs 
suggestive of genetic disorder or skeletal muscle disease, and stroke, especially at an early 
age should be queried. The personal and family histories are mainly targeted towards 
identifying genetic cardiomyopathy. However, history or signs of autoimmune disease, 
such as diabetes mellitus type I, or inflammatory disease, such as sarcoidosis and giant cell 
myocarditis, should not be forgotten. (11) Regarding cardiac sarcoidosis improved 
diagnostics has lead to a marked increase in its detection rate.  (21)
Standard electrocardiogram (ECG) can guide towards specific diagnosis in certain 
cases, such as atrioventricular block (AV block), low amplitude P waves, or sinus 
bradycardia in laminopathy caused by LMNA mutations (22, 23), or ventricular pre-
excitation or AV-block in storage diseases. (24, 25) Some laboratory parameters, such as 
creatine kinase, kidney and liver function tests, haemoglobin and white blood count, 
ferritin, calcium, phosphate, thyroid function tests, should be taken from all DCM patients, 
and some, such as autoantibodies, titres for infectious agents, thiamine, urine or plasma 
catecholamines, and angiotensin converting enzyme, based on clinical evaluation and the 
suspicion of specific diagnoses. (11) Coronary angiography is often performed to rule out 
coronary artery disease as a cause for the DCM phenotype. In some cases CMR might be 
sufficient, and due to its non-invasive nature preferable, as a first-line diagnostic tool in 
determining the cause of heart failure of unknown aetiology. (26) However, controversy 
remains on the ability of CMR to rule out ischemic heart disease. (27) A non-invasive 
imaging modality better suited for the study of coronaries is coronary CT. (28) When 
inflammatory cardiomyopathy is suspected 18-F-fluorodeoxyglucose positron emission 
tomography (18F-FDG PET/CT) is the preferable imaging modality to date due to its 
ability to detect inflammatory processes in the myocardium. (29) 
The frequency of the usage of endomyocardial biopsy in the diagnostic process of 
dilated cardiomyopathy varies. The procedure is not free from risk, but can be useful in 
differential diagnosis, in particular, identifying myocarditis or cardiac sarcoidosis patients 
who can benefit from immunosuppressive therapy. (30, 31) Inflammatory 
cardiomyopathy, or myocarditis, is myocardial disease caused by an inflammatory process 
of varying aetiology, e.g. viral, autoimmune, or toxic. Also the clinical presentation varies 
as the condition can be asymptomatic and self-limiting, or can progress to DCM. A definite 
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diagnosis requires histological confirmation. (32) Due to these reasons inflammatory 
cardiomyopathy is difficult to study, and estimates of its significance as a cause of 
idiopathic DCM vary. (32-34) Two studies, using endomyocardial biopsy and the Dallas 
criteria (35) for the histopathologic diagnosis of myocarditis reported similar prevalences 
of 9.2% (36) and 9.6% (37) of myocarditis among patients with idiopathic DCM.  
 
?????? ??????????????????????????????
An abnormal ECG can often be the first sign suggestive of dilated cardiomyopathy. 
However, the ECG abnormalities seen in DCM are usually not specific to DCM or familial 
DCM.  (38, 39) Instead they can raise the clinical suspicion of heart disease leading to 
further examination, usually echocardiography, and diagnosis. (11) Yet some ECG 
abnormalities are typical to certain genetic etiology. In cardiolaminopathy common ECG 
abnormalities include low-voltage P wave, progressive conduction system disease, and 
both atrial and ventricular arrhythmias. (22, 23, 40) In laminopathy ECG abnormalities 
tend to precede structural disease. (23) Additionally to LMNA mutation carriers 
conduction system disease is also seen more often in DCM patients with RNA binding 
motif protein 20 (RBM20), beta-myosin heavy chain (MYH7) (41) and sodium voltage-
gated channel alpha subunit 5 (SCN5A) mutations (15) than in other DCM patients. In 
phospholamban mutation carriers low voltage is prevalent and ventricular arrhythmias are 
more common than in other DCM patients. (41) In conclusion some genetic forms of DCM 
have typical ECG characteristics that can be suggestive of the genetic etiology, but no ECG 
abnormalities are specific to a certain genetic etiology.  
 
?????? ?????????????????????????????????????
The clinical presentation of DCM ranges from asymptomatic to end-stage heart failure. 
Disease onset occurs typically in adulthood, but can take place already in infancy. (15) In 
contrast to adult DCM, paediatric cardiomyopathy has worse prognosis (42) and is a lot 
more rare, with an incidence of 1.24: 100 000 in Australia in 1987-1996, (43) 1.13: 100 000 
in the United States in 1996-1999, (44) and 0.34: 100 000 in Finland in 1980-1991. 
Symptomatic DCM patients often present with symptoms of heart failure, such as 
dyspnoea, exercise intolerance, fatigue, or hepatomegaly and peripheral oedema when also 
right ventricular dysfunction is present. If valvular regurgitation is present, a heart 
murmur can be heard in auscultation. Other auscultation abnormalities include a gallop 
and tachycardia. (15, 45) Arrhythmias, such as atrial fibrillation or other atrial arrhythmias 
and ventricular tachycardia, can also be the main symptom leading to cardiac assessment 
and diagnosis. Other electrophysiological or ECG abnormalities include atrioventricular 
blocks, ST-T abnormalities, bundle-branch block, and Q waves. Sometimes DCM diagnosis 
is reached following a thromboembolic complication, or the chance finding of 
cardiomegaly in a routine chest x-ray. (45) Sudden cardiac death (SCD) may also be the 
first disease presentation of DCM. (15) 
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The treatment of DCM follows the general guidelines of heart failure management. The 
use of angiotensin converting enzyme inhibitors delays the onset of symptoms and reduces 
the risk of death or hospitalization due to heart failure in asymptomatic patients with 
reduced LVEF. Angiotensin receptor blockers can be used instead in patients who have 
adverse effects to angiotensin converting enzyme inhibitors. Beta-blockers are also 
recommended, although the prognostic advantage in asymptomatic patients is not as clear. 
In symptomatic patients ACIs and beta-blockers should be used as they favour prognosis. 
(46) The newest addition to the treatment of heart failure is an antihypertensive drug 
sacubitril, which inhibits neprilysin, an enzyme degrading atrial and brain natriuretic 
peptides. The combination of sacubitril and valsartan in comparison to enalapril has been 
shown to reduce the risk of death and hospitalization due to heart failure. (47)  
Diuretics and dietary salt and fluid restriction is recommended to patients with fluid 
retention. Drugs known to be harmful, such as non-steroidal anti-inflammatory drugs 
should be avoided. Digoxin can be used to alleviate symptoms of heart failure. Aldosterone 
antagonists can improve prognosis in symptomatic patients and can be used with close 
serum potassium and renal function monitoring. (46, 48) 
Tachycardia can worsen the cardiomyopathy phenotype or even cause it, (49) and 
consequently, the ventricular response in atrial fibrillation should be controlled or sinus 
rhythm restored in DCM patients. (48) Anticoagulation is currently recommended only to 
those DCM patients with atrial fibrillation (50) following the general recommendations, 
and using the CHA2DS2-VASc (51) and HASBLED (52) risk stratification tools for 
thromboembolic events and major bleeding, respectively.  
The risk of SCD is high among DCM patients. (53) SCD can result from either 
ventricular tachycardia, ventricular fibrillation, or bradyarrhythmia. (54) Implantable 
cardioverter-defibrillators (ICDs) are used both in primary and secondary prevention of 
ventricular arrhythmias in DCM patients. In secondary prevention, ICDs reduce the risk of 
mortality, and are indicated in patients with otherwise good prognosis. (46) The patient 
selection for primary prevention is based on LVEF, and ICD implantation is recommended 
to symptomatic patients with an LVEF less than or equal to 35% and otherwise good 
prognosis. (46) However, SCD often occurs in DCM patients who do not meet the LVEF 
criterion, and, on the other hand, many who do never undergo an appropriate ICD event. 
Thus, it is recognised that better tools for risk-stratification and other preventive measures 
are needed for optimal SCD prevention. (54) 
Sinus node dysfunction and AV blocks resulting in symptomatic bradycardia are treated 
with pacemaker therapy in DCM as in other heart disease. (55) Cardiac resynchronization 
therapy (CRT) is used to treat ventricular dyssynchrony resulting in suboptimal ventricular 
filling and greater severity of mitral regurgitation. Prognostically ventricular dyssynchrony 
leads to increased mortality, (56) and treatment with CRT in turn decreases mortality in 
appropriately selected patients. (57) 
The survival rates of heart failure patients have improved in the last decades. (58) 
There has also been advancement in the prognosis of acute decompensated heart failure 
requiring hospitalization, but in a recent population-based American study the five-year 
post-discharge survival in patients hospitalized in 2004 was still under 30%. (59) Patients 
with comorbidities had a worse prognosis. It is likely that patients with heart failure due to 
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coronary heart disease have more comorbidities than DCM patients, so the prognosis for 
heart failure due to DCM might not be as grim. Heart transplantation is a treatment option 
for end-stage heart-failure patients, and DCM is the most frequent cause for heart 
transplantation. (1) In Finland, 411 patients had undergone heart transplantation by 2010, 
and in recent years, some 15-20 heart transplantations have been performed annually. 
(60) Left ventricular assist devices can be used as a “bridge” to heart transplantation or as 
destination therapy for select patients who are not eligible for transplantation. (46, 48)   
Current treatment strategies have altered the prognosis of DCM. In some cases even 
improvement in LVEF as well as reduction in LVEDD, referred to as reverse remodelling, 
is seen. (61) Recently diagnosed disease, non-familial disease, pregnancy-associated 
disease, left-ventricular hypertrophy (defined as left-ventricular wall thickness of 12mm or 
more in echocardiography), and an initial LVEF ? 25% have been identified as 
independent predictors of persisting improvement of LVEF defined as LVEF improved by 
at least 10 % units seen in at least two echocardiography examinations with a minimal time 
interval of 12 months. (62) Due to the possible improvement with appropriate 
pharmacological treatment it is recommended that ICD implantation in primary 
prevention should not be performed before at least 3 to 6 months of appropriate medical 
therapy. (63) Furthermore, as a nationwide Danish study shows, complications following 
cardiac implantable electronic devices are more frequent than previously thought, 
illustrating the need to assess the possible risks as well as the benefits before implanting 
any cardiac electronic device. (64) 
Currently genotype affects treatment and follow-up of individual patients in only a 
minority of cases, in which the phenotype is clearly distinct. For instance, for LMNA 
mutation carriers ICD implantation under looser LVEF criteria than for other DCM 
patients can be reasonable. (65-68)  
 
?????? ?????????????????????????????????
Cardiopulmonary exercise testing (CPET) is used to measure cardiorespiratory fitness, 
assess the mechanisms underlying reduced ability to exercise, and make prognostic 
estimates in various diseases. Prognostic stratification can in turn guide clinical decision-
making, for example when assessing eligibility for heart transplantation. In 
cardiopulmonary exercise testing ventilatory gas exchange is measured non-invasively 
during progressive exercise. (69)  
Cardiopulmonary testing variables with prognostic significance in heart failure are peak 
oxygen consumption (V̇O2), slope of ventilation/CO2, i.e. V̇E/V̇CO2 slope, exercise 
oscillatory ventilation, and resting or exercise partial pressure of end-tidal carbon dioxide, 
the first two being the most established variables. (69-71) Peak oxygen consumption is the 
most widely used prognostic marker in heart failure with low values, especially below a 
cut-off value of 14 ml kg-1 min-1 predicting mortality and traditionally used in heart 
transplantation eligibility assessment. (71-73) In recent years V ̇E/V̇CO2 slope, not relying 
on maximal exertion, has been proposed as a more reliable prognostic marker in heart 
failure. (71) Variables with prognostic value respond to appropriate pharmacological, 
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surgical and lifestyle interventions, and can also in that respect be useful in clinical 
decision-making. (69, 74, 75) During exercise heart failure patients have a tendency to 
hyperventilate, and a reduced ventilatory efficiency is seen resulting in an elevated V̇E/ 
V̇CO2 slope. (76) CPET studies often comprise of heart failure patients with variable 
etiology, (71, 77-83) which is a possible limitation when drawing conclusions from them 
concerning DCM patients. A study addressing the prognostic value of cardiopulmonary 
exercise testing variables in dilated cardiomyopathy patients identified V ̇E/V̇CO2 slope > 
29 and percent-predicted maximal oxygen consumption (VO2%) <60% as the best 
predictors for death or urgent heart transplantation. (84) 
Multiple mechanisms have been proposed to underlie the inefficient ventilation in heart 
failure: increased dead space, early development of lactic acidosis caused by an inability to 
increase cardiac output to correspond to metabolic demand, and changes in breathing 
control related to changes in both chemoreflex and metaboreflex control. (85, 86)  
???? ?????????????????????????????????
???????????????
 
ARVC (previously ARVD for arrhythmogenic right ventricular dysplasia) is a familial heart 
muscle disorder characterized by fibrofatty replacement, dilatation, and abnormal 
contraction of the right ventricle. Increasingly also left ventricular and biventricular forms 
are being recognised. Ventricular arrhythmia is a typical feature of ARVC and can cause 
SCD already in early adulthood. (87, 88) The mode of inheritance is typically thought of as 
autosomal dominant, although other forms of inheritance have been identified. (87-89)  
Desmosomes, cell-to-cell adhesion junctions found in abundance in the heart and the 
epidermis, bind cardiomyocytes to each other enabling synchronized contractility. 
Together with gap junctions, which allow for the fast ion flux within the myocardium, and 
adherens junctions, desmosomes reside in the intercalated disc of the cardiomyocytes 
joining adjacent cardiomyocytes together. Desmosomes also play a part in wound-repair 
during which they forgo their normal hyperadhesiveness for a more dynamic state. 
Intracellularly desmosomes are connected to the cytoskeleton. (89) Mutations in 
desmosomal genes were first identified in skin fragility conditions. (90) A homozygous 
plakoglobin (JUP) mutation was then connected to Naxos disease characterized by 
palmoplantar keratoderma, woolly hair, and ARVC. (91) Since then several other 
desmosomal genes have been implicated in ARVC, namely, desmoplakin (DSP), 
plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2). Additionally 
some non-desmosomal genes, such as transforming growth factor-β3 (TGFβ3), 
transmembrane protein 3 (TMEM3), and LMNA have been connected to ARVC. (87, 91, 
92) 
The original 1994 Task Force criteria (93) for the diagnosis of ARVC were based on 
knowledge gathered from symptomatic index cases and SCD victims and, thus, 
represented the most affected ARVC cases, but lacked sensitivity to identify the less severe 
phenotypes. (87) The 2010 revision to the criteria was aimed to increase sensitivity. 
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Among other adjustments it includes pathogenic genotype and recognises family members 
with looser criteria. (87) The diagnosis is still based on a compilation of major and minor 
criteria from different areas, including morphology (echocardiography, CMR, 
angiography), biopsy, ECG, signal averaged ECG, typical arrhythmias, family history, and 
genetic analysis. 
Apart from ARVC, desmosomal mutations have also been linked to DCM. Elliot et al. 
(94) found desmosomal mutations in PKP2 and DSP from five patients from a cohort of 
100 DCM patients who did not fulfil ARVC criteria or have ARVC in family history. The 
PKP2 mutation c.419C>T, p.(Ser140Phe) found in three probands had previously been 
reported in ARVC patients whereas the two DSP mutations were novel. Similarly Garcia-
Pavia et al. (95) found desmosomal mutations considered pathogenic in 13% (12/89) of 
DCM patients who had undergone heart transplantation. Again none of the probands 
fulfilled ARCV criteria nor had ARVC in family history. However, most (9/12) patients 
presented with at least one minor ARVC diagnosis criterion. 
On the other hand, ARVC-associated mutations have also been found in the general 
population highlighting the need for broad population-based reference datasets. Lahtinen 
et al. reported ARVC-associated desmosomal mutations at a 0.5% frequency in a Finnish 
population cohort of over 6000 individuals. (96) The most prevalent was a PKP2 
c.176A>T, p.(Gln59Leu) mutation found in 0.3% of the cohort. The same variant had 
previously been found in two unrelated ARVC probands and eight family members of 
whom only one fulfilled the modified ARVC criteria for family members. (97) Functional 
evidence from epithelial cell lines suggests that the mutation disrupts contact with 
desmoplakin. (98) These studies combined it seems that the PKP2 c.176A>T, p.(Gln59Leu) 
mutation is not harmless, but it is unclear whether it is enough to cause disease on its own. 
Interestingly in the Garcia-Pavia study of end-stage DCM patients four out of the 12 
patients with desmosomal mutations had two mutations. (95)  
 
???? ????????????????????????
 
Up to 30-50% of DCM is currently considered familial or genetic, (18, 99) although 
estimated proportions vary depending on the specific phenotype and age group studied. 
(100) Over 40 genes have been related to DCM and about a hundred to cardiomyopathies 
in general. (99) Mutations in practically any structure or pathway of the cardiomyocyte can 
result in the DCM phenotype. (99) Recent advancement in the study of the genetics of 
cardiomyopathies has lead to an understanding about the presence of genetic and 
phenotypic overlap in DCM, HCM, and ARVC. (18, 100) Familial DCM is typically 
considered a monogenic disorder, but it is possible that especially in the case of sporadic 
disease the genetic etiology is more complex involving the interaction of several possibly 
common variants and environmental effects. (18, 100)  
In the 2008 ESC classification of cardiomyopathies familial cardiomyopathy is defined 
quite loosely as the occurrence of the same disorder or phenotype that is or can be caused 
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by the same genetic mutation in more than one family member. (4) For research purposes 
other varying definitions for familial (dilated) cardiomyopathy have also been used. (12, 
101) When only oral family history is used to assess whether the disease is familial, the 
proportion of familial DCM is underestimated as opposed to the situation where family 
members are examined using echocardiography. (102)
Dilated cardiomyopathy is most often inherited in an autosomal dominant pattern, 
often with an age-dependent penetrance. (22, 103, 104) However, recessive, (18) X-linked, 
(6) and mitochondrial (105) forms have been identified. The recessive conditions often 
represent syndromic or metabolic diseases, (18) and, similarly, in the case of metabolic 
diseases the mode of inheritance is usually recessive or X-linked. (103) Thus, drawing the 
pedigree is essential in determining the mode of inheritance and can even give clues as to 
what the genetic etiology might be. The age-related penetrance makes assessing the 
presence of a familial cardiomyopathy complicated especially in the case of children and 
young adults. (18, 103) Other challenges when estimating whether cardiomyopathy is 
familial are small family size, especially in Western countries, (106) and the tendency 
among patients and even clinicians to refer to any cardiac event as “heart attack”. (18) 
These obstacles put together make it understandable that cardiomyopathy appearing to be 
sporadic can often have a genetic etiology.    
???? ???????????????????
 
The majority of individual genes thought to cause DCM explain only a small fraction of the 
disease burden. (18, 107) On the other hand truncating mutations of titin (TTN), the most 
prevalent genetic cause of DCM, explain 11-18% of sporadic and up to 19-25% of familial 
DCM with variation depending on disease severity. (18, 101, 106, 108, 109) Mutations of 
LMNA, encoding Lamins A and C of the nuclear lamina, are the second most prevalent 
cause of DCM explaining 5-8% of familial DCM. (107) In the Finnish population LMNA 
mutations have been found in 9% of heart transplant recipients with DCM, (110) while in 
an other study the Finnish founder mutation c.427T>C, p.(Ser143Pro) was found in 7% of 
Finnish DCM probands. (111) Mutations in sarcomeric proteins, such as alpha-myosin 
heavy chain (MYH6), beta-myosin heavy chain (MYH7), myosin-binding protein C 
(MYBPC3), myopalladin (MYPN), and cardiac troponin T (TNNT2), have been thought to 
explain 2-4% of DCM each with some genetic overlap to HCM. (18, 112) Several 
cytoskeleton proteins have been thought to cause up to 1% of DCM each. (18) The 
desmosomal proteins desmoplakin (DSP), desmocollin-2 (DSC2), and desmoglein-2 
(DSG2) have been associated with DCM as well as ARVC. (18, 95) RBM20 is a DCM-gene 
expressed in striated muscle, especially the heart, functioning in the regulation of splicing 
of titin and other cardiomyopathy-related genes associated with sarcomere-organization 
and ion transport in the sarcoplasmic reticulum. (113) It might explain up to 3% of 
idiopathic DCM. (114, 115) Table 1 lists genes associated to DCM.  
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ABCC6 ATP-binding cassette subfamily C member 6 
?????? ATP-binding cassette subfamily C member 9 
?????? alpha-actin 1 
?????? alpha-cardiac actin 
?????? actinin alpha 2 
?????? Alström syndrome 1 
?????? alpha-kinase 3 
?????? apolipoprotein A-I 
????? BCL2-associated athanogene 3 
???? Desmin 
???? Dystrophin 
????? dolichol kinase 
????? desmocollin 2 
????? desmoglein 2 
???? Desmoplakin 
????? Dysferlin 
??????? eukaryotic translation elongation factor 1 alpha 2 
???? Emerin 
????? ectopic P-granules autophagy protein 5 homolog 
????? electron transfer flavoprotein alpha subunit 
????? electron transfer flavoprotein beta subunit 
?????? electron transfer flavoprotein dehydrogenase 
??????? F-box protein 32/atrogin 1 
????? Fukutin 
????? filamin C 
?????? forkhead box D4 
?????? GATA binding protein 6 
????? glycogen branching enzyme  
????? galactosidase beta-1 
?????? heart and neural crest derivatives expressed 1 
????? hyperpolarization activated cyclic nucleotide-gated potassium channel 4 
????? junctophilin 2 
???? (junction) plakoglobin 
?????? lysosomal-associated membrane protein 2 
????? lamin A/C 
??????? leucine rich repeat containing 10 
?????? malonyl-CoA decarboxylase 
??????? myosin binding protein C 
??????? myosin binding protein H-like 
????? myosin heavy chain 6 
????? myosin heavy chain 7 
????? myosin light chain 4 
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????? propionyl CoA carboxylase alpha subunit 
????? Propionyl CoA carboxylase beta subunit 
????? plakophilin-2 
???????? pleckstrin homology and RUN domain containing M2 
???? Phospholamban 
??????? PR domain containing 16 
????? v-raf-1 murine leukemia viral oncogene homolog 1 
?????? RanBP-type and C3HC4-type zinc finger-containing protein 1 
?????? RNA binding motif protein 20 
?????? required for meiotic nuclear division 1 homolog 
?????? sodium voltage-gated channel alpha subunit 5 
????? SPEG complex locus 
????? TGF-beta activated kinase 1 
???? Tafazzin 
????? T-box 5 
?????? T-box 20 
????? telethonin/titin-cap 
?????? troponin C type 1  
?????? troponin I type 3 
??????? TNNI3 interacting kinase 
?????? (cardiac) troponin T type 2 
????????? torsin A interacting protein 1 
????? Tropomyosin 
???? Titin 
???? Transthyretin 
???? Vinculin 
??????? vacuolar protein sorting 13 homolog  A 
 
????????? ??????????????????????????? ??????????????????????????????????? ?????????????????????????????
??? ?????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
 
???? ?????????????????????????????????????
 
Clinical screening of first-degree family members of DCM patients is recommended to 
enable early diagnosis. There is evidence to suggest that early diagnosis allowing early 
pharmacological interventions and clinical counselling can improve patient outcomes. (15, 
116) At least in the case of known familial disease the clinical evaluation of first-degree 
relatives should happen repeatedly, every 2-5 years in adulthood until age 50-60, by which 
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age the penetrance of most genetic cardiomyopathies is full, whereas in the sporadic form 
repeated evaluation might not be necessary. (103) A recent nationwide study from 
Denmark showed that a family history of sudden death from cardiomyopathy in a first 
degree relative before the age of 60 increases the risk of cardiomyopathy 30-fold and up to 
100-fold if the relative died before age 35. (117) A purpose for genetic testing in dilated 
cardiomyopathy is that the discovery of a disease-causing mutation allows the genetic 
testing of relatives freeing those not carrying the disease-causing mutation and not at risk 
to develop disease from follow-up thus making the allocation of clinical resources to those 
at risk possible. (103) Genetic testing and a possible genetic diagnosis can also influence 
clinical decision-making in the individual patient. For instance LMNA mutation carriers 
are at a high risk for malignant ventricular arrhythmias, and can, in the presence of certain 
risk factors, namely male gender, non-missense mutation (i.e. insertion, deletion, 
truncating mutation, or a mutation affecting splicing) or non-sustained ventricular 
tachycardia (NSVT), benefit from ICD implantation even when the ventricular function is 
somewhat conserved. (68) Therefore receiving a cardiolaminopathy-diagnosis can favour 
ICD-implantation under less strict criteria than in other DCM patients. Similarly, 
mutations in the ion-channel gene SCN5A have been associated with a somewhat high 
frequency of ventricular and other arrhythmias. (118) With the emergence of next-
generation sequencing (NGS) technologies there are hopes for a more extensive 
characterization of genotype-phenotype correlations affecting clinical decision-making in 
DCM. However in the context of more comprehensive genetic testing in larger numbers, it 
is certain that the number of variants of unknown significance (VUS) found will also rise. 
(99) In this scenario it is more likely to receive an initial VUS-diagnosis than a conclusive 
genetic diagnosis. (101) Naturally the discovery of a VUS makes the follow-up of relatives 
less straightforward as no one is entirely freed from risk of developing the disease 
regardless of whether they carry the identified VUS or not. 
The ESC Working Group for Myocardial and Pericardial Diseases recommends that 
when possible, genetic testing should be targeted to the likely diagnosis. (11) The current 
tendency, however, is towards large, comprehensive test panels aimed to cover all 
cardiomyopathy-related genes. (101, 106) The inevitable consequence of this trend is not 
only more DCM-patients receiving a genetic diagnosis, but also many receiving 
inconclusive results from genetic testing with the above-mentioned consequences. (18, 
100, 101) When genetic testing is performed the individual with the most severe phenotype 
should be the one to undergo testing. (18) As the understanding of the genetics of 
cardiomyopathies is evolving continuously, also the process of genetic counselling in a 
family with cardiomyopathy patients can and perhaps should be seen as a dynamic 
process. (99) This is particularly important in families and individuals with inconclusive 
test results from genetic testing. Genetic counselling should be incorporated into the 
process of genetic testing. Patients should be informed about the aims, possibilities, 
limitations and possible consequences of genetic testing before undergoing the testing. 
(119) In the management of patients and families with hypertrophic cardiomyopathy there 
is evidence to support cost-effectiveness of genetic testing. (120, 121) Although this is not 
yet the case in DCM, it likely will be with the rapid advances made in the field of genetics of 
DCM.  
  28 
???? ???????????
 
Genetic testing in cardiomyopathies, as in other genetic conditions, previously relied on 
Sanger sequencing of individual genes, which was time-consuming and lead to only a small 
fraction of patients receiving a genetic diagnosis even in cases of known familial disease. 
(38) The development of next-generation sequencing methods have enabled the 
simultaneous study of all desired genes related to a given condition, the whole exome or 
even the entire genome in a matter of days and at a reasonable cost. (99, 119)  
Oligonucleotide-selective sequencing (Os-Seq) is a targeted sequencing method where 
target genomic areas are captured and sequenced on the solid Illumina flow cell. (122) The 
Os-Seq method is based on first synthesizing the target-specific oligonucleotides and 
immobilizing them on the sequencer flow cell.  Then a DNA library is prepared by shearing 
the sample DNA into fragments and ligating known adapter sequences to the ends of the 
DNA fragments. The library is then added to the flow cell in which the target areas are 
captured, amplified and sequenced. The sequence analysis is based on detecting 
fluorescently labelled nucleotides while they incorporate to the growing DNA strand. (122, 
123) Os-Seq has been shown to capture target regions effectively and specifically with a low 
false-positive rate, and it allows the creation of a customized targeted sequencing platform. 
This makes the method suitable for the study of diseases in which a large number of genes 
are implicated. (122)  
In exome sequencing the target area for sequencing is the roughly 1% of the genome 
consisting of exons, whereas in whole genome sequencing the aim is to sequence the entire 
genome. However, in current reality varying portions of the genome, depending on the 
sequencing platform and the area in question, are not covered adequately to draw 
conclusions from. (124) Positive findings acquired by next-generation sequencing methods 
are still often confirmed with Sanger sequencing. (93)   
For all types of next-generation sequencing, namely targeted, exome and whole-
genome sequencing, the amount of data generated is enormous, and consequently, 
expertise in bioinformatics is required for data analysis. (119) Furthermore, next-
generation sequencing approaches bring about the issue of distinguishing rare but benign 
frequencies from actual disease-causing mutations. Strict criteria for variant classification 
should be used, as classifying a variant pathogenic will most likely affect the treatment and 
follow-up of the patient carrying the variant as well as both carrier and non-carrier family 
members. (100, 125)  
 
???? ???????????????????????
 
Advancements in next-generation sequencing have lead to an increase in the clinical 
sensitivity of genetic test panels. On the other hand the number of inconclusive test results 
rises alongside with the number of genes studied in a genetic test panel. (126) In a study by 
  29 
Pugh et al. the proportion of DCM patients receiving a VUS-diagnosis increased 10-fold, 
from 4.6% to 51%, as the panel size increased from five to 46 genes. (101) Variant 
classification is a process taking in account several lines of evidence to come up with a 
conclusion about the pathogenicity of a variant. In 2015 the American College of Medical 
Genetics and Genomics gave a recommendation to guide variant interpretation. (125) This 
guideline answered a clear demand, as without such a reference, discordance between 
reviewers assessing the pathogenicity of a variant is common. If two reviewers come up 
with differing views on pathogenicity, it is likelier that the less pathogenic assessment is 
correct upon revision. (127) The American College of Medical Genetics and Genomics 
guideline recommends the division of variants into five categories, namely: pathogenic, 
likely pathogenic, uncertain significance, likely benign, and benign. There are multiple 
lines of evidence for assessing the pathogenicity of a variant, such as segregation of the 
disease phenotype with the variant, the allele frequency of the variant in a population 
database, evidence of pathogenicity from functional assays, assessment of scientific 
literature, type of mutation, and in silico prediction tools. Variant classification should be 
seen as a dynamic, on-going process taking in account all available evidence favouring or 
opposing pathogenicity. With increasing evidence initial diagnoses, especially VUS-
diagnoses, are likely to change over time. It is thus important to create systems in genetics 
laboratories to systematically review, and if necessary change, previous classifications. 
(125, 128)  
 
?????? ???????????????
With the detection of large numbers of variants per test, the significance of the segregation 
of the disease with the variant has, if possible, increased. (129) The logarithm of odds 
(LOD) score is a mathematical means of assessing co-segregation in a pedigree, with a 
positive LOD score suggesting linkage. (130) When choosing the threshold for a significant 
LOD score the context should be taken in account, for example whether the locus or gene 
of interest is previously known to be associated with the disease. (126, 127) The 
interpretation of co-segregation is complicated by incomplete or age-dependent disease 
penetrance, and thus in the case of cardiomyopathies unaffected individuals should not be 
included in segregation-analysis especially at young age. (126) However, an affected 
individual in a pedigree not carrying the candidate variant is strong evidence against 
pathogenicity. In general, the more individuals there are available for analysis preferably 
from multiple families, the more reliable the assessment of co-segregation. (125) Roughly 
ten available segregations for assessment are needed to obtain a LOD score >3 
traditionally considered sufficient proof of segregation. (126) 
 
?????? ??????????????????
A de novo mutation in a disease-associated gene in an individual with the disease not 
present in either parent is strong evidence of pathogenicity of the variant. However, 
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parentage must be confirmed, and the possibility of a sampling error must be excluded. 
(126, 127) 
 
?????? ????????????????????????????????????????????????????
High allele frequency (AF) in a reference population is a strong indication of a benign 
variant in disorders of dominant inheritance. However, a founder mutation in a population 
with a relatively high incidence of the disorder in question might have a slightly higher 
allele frequency. When assessing the allele frequency, disease prevalence should be taken 
in account. If the allele frequency is greater than the expected frequency of the disease, the 
variant is very likely benign. (125) The largest reference population database to date is the 
Genome Aggregation Database (gnomAD) containing exome sequencing data from over 
120 000 individuals, as well as whole genome sequencing data from over 15 000 
individuals.  
GnomAD is most efficient in filtering candidate variants when population-specific 
subsets are used. From a Finnish standpoint gnomAD provides a good opportunity for this 
as it contains the exome data of over 11 000 and whole genome data of 1747 Finns. The 
Exome Aggregation Consortium (ExAC), containing exome sequencing data from over 60 
000 individuals, including a subset of some 3000 Finnish individuals, was the predecessor 
of gnomAD. On average individuals in ExAC carry 53 variants, which have been reported 
disease-causing in disease databases. However, 41 of these variants have an AF of >1% in 
at least one population found in ExAC supporting the idea that there is an abundance of 
false-positives in disease databases. (131)  
 
?????? ????????????????????
Functional analysis can offer additional proof of pathogenicity of a variant. If a functional 
assay is performed, the assay used needs to be well correlated with the studied disorder 
and validated with known variants. Availability issues as well as interpretation difficulty 
limit the use of functional assays especially in clinical context. (127) Functional data can 
appear contradictory and should thus be viewed with caution and when possible in a wider 
context. For instance, protein kinase AMP-activated non-catalytic subunit gamma 2 
(PRKAG2) mutations cause a cardiac phenotype characterised by electrophysiological 
disturbances, typically pre-excitation, glycogen-containing storage-vacuoles, and left-
ventricular hypertrophy. (132) In an attempt to assess the specific cellular mechanisms 
behind the phenotype functional studies have been performed with conflicting results; in 
murine models both increased and decreased activation of adenosine monophosphate-
activated kinase (AMPK) have been seen. (133, 134) AMPK is a protein kinase, which 
normally activates during energy depletion, and PRKAG2 encodes the Υ2-subunit of this 
protein kinase. An explanation to these apparently contradictory findings seen in murine 
models is that PRKAG2 mutations cause an initial increase in the activation of AMPK, but 
as glycogen accumulates in the cardiomyocyte, AMPK activity is downregulated. (135) 
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Thus looking at only one functional study would give an incomplete view of the 
mechanisms behind cardiomyopathy caused by PRKAG2 mutations.     
In the recent paper by Lek et al. introducing the ExAC 192 variants found in ExAC and 
previously considered pathogenic were reassessed for evidence of pathogenicity. 163 of 
them were reclassified as likely benign or benign. Furthermore, 18 of these reclassified 
variants had functional data supporting pathogenicity. (131)   
 
?????? ?????????????????????
Currently most in silico tools predict whether missense mutations are damaging to the 
protein structure or function or whether there is an effect on splicing. The tools assessing 
the effect of missense mutations are based on evaluating evolutionary conservation, the 
location of the variant in the gene, and/or the biochemical consequence of the amino acid 
change. (125) In silico tools that can additionally predict the effects of insertions and 
deletions (indels) are also starting to appear. (136) As in silico tools have varying accuracy 
evaluating known pathogenic variants and a known tendency to overestimate 
pathogenicity; they should never be used as a sole line of evidence in variant analysis. (125, 
137) 
 
???? ?????????????????????????????
 
?????? ?????????????????
Lamins A and C of the intermediate filament family encoded by the LMNA gene locate in 
the nuclear lamina on the nuclear side of the inner nuclear membrane. Besides structural 
proteins they are thought to function in transcription, replication and signalling. LMNA 
mutations cause a variety of clinical phenotypes, such as muscular and lipodystrophies, 
neuropathy, Hutchinson-Gilford progeria syndrome causing premature aging, and 
cardiomyopathy. The broad spectrum of disease, or laminopathy, caused by LMNA 
mutations seems to be connected to varying expression and functions of lamins in different 
tissues at distinct developmental stages. (138) 
Cardiomyopathy caused by LMNA mutations typically follows an age-dependent course 
first manifesting in early adulthood as electrical abnormalities, such as low amplitude P 
wave, atrioventricular block, atrial and ventricular arrhythmias, and need for a pacemaker, 
and later progressing to dilated cardiomyopathy. (15, 22, 23, 139) Although the left 
ventricular dilatation can appear modest in cardiolaminopathy, the disease can advance to 
end-stage heart failure requiring heart transplantation. (15, 110) Besides DCM, LMNA 
mutations have also recently been linked to a right-dominant cardiomyopathy. (92) 
Functional studies suggest that DCM-causing LMNA mutations might lead to impaired 
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assembly of the nuclear lamina and reduced cellular stress tolerance especially in cells, 
which are under constant mechanical stress. (140) 
 
 
?????? ????????????
Titin, the largest known protein with a molecular mass of up to 4 MDa, consists of 363 
exons and comprises four distinct regions spanning half the length of the sarcomere. The 
N-terminal part anchors the protein to the Z-disk playing a role in myofibril assembly and 
the maintenance of sarcomere structure. (141, 142) The elastic I band, which is a site of 
extensive alternative splicing, acts as a spring restoring sarcomere length after systole and 
on the other hand limiting sarcomere length in early diastole. (109, 143) The constitutively 
expressed A-band binds to myosin and myosin-binding protein and connects to the C-
terminal M-band, which contains a strain-sensing kinase and is thought to respond to 
changes in mechanical strain by partaking in signalling and affecting gene expression. 
(109, 144) The major cardiac isoforms of titin are the longer N2BA and the shorter and 
stiffer N2B isoform; additionally a short novex isoform is expressed in low quantities in 
adult human heart. (141) The expression ratios of these isoforms vary between species but 
also within the heart resulting in changes in myocyte stiffness and diastolic force 
generation. (145) A schematic of titin within the sarcomere is shown in Figure 2. 
In 2002 two co-segregating TTN-mutations in large pedigrees were reported to cause 
familial DCM. One was a truncating mutation located in the A band and the other a 
missense mutation in a conserved location in the Z-disc-I-band transition zone speculated 
to disrupt Z disc architecture. (146) Due to the large size and variation of TTN it took 
another decade and the development of next-generation sequencing methodology to 
establish its important role in DCM. Herman et al. were the first to report that truncating 
TTN variants (TTNtv) are the most important genetic cause of dilated cardiomyopathy. 
They reported that 25% of familial DCM patients and 18% of sporadic cases harbour 
truncating TTN mutations. However, also 3% of the control group and 1% of the HCM 
group had TTNtvs. Furthermore, each HCM patient harbouring a TTNtv also had a 
mutation in a well-established HCM-related gene (MYH7 or MYBPC3). (108) Several 
studies confirmed the relevance of TTN in dilated cardiomyopathy, but the question of the 
prevalence of TTNtvs in the reference databases remained. Pugh et al. reported a 
prevalence of 14% of TTNtvs in their DCM cohort and 1.65% in the National Heart, Lung 
and Blood Institute Grand Opportunity Exome Sequencing Project (ESP). (101) Roberts et 
al. reported a similar prevalence of 13% TTNtvs in unselected DCM patients and a higher 
22% in end-stage DCM patients. In the three control groups they used, the Jackson and 
Framingham Heart Studies and a healthy volunteer group, TTNtv prevalence was 1.6%, 
1.0%, and 2.9%, respectively. They estimated the prevalence of TTNtvs in the general 
population to be roughly 2% based on the ESP and 1000 Genomes databases and figures 
reported in earlier studies. (108, 109, 147) In a large study based on DCM patient-sets from 
eight countries Haas et al. found a TTNtv prevalence of 11% for sporadic and 19% for 
familial DCM. (106) Already in the study of Herman et al. it was shown that the DCM-
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associated TTNtvs were concentrated on the A-band region whereas those observed in the 
controls were more uniformly distributed. The study by Pugh et al. confirmed this 
difference in the distributions of TTNtvs in DCM cases and controls. (101) 
Approaching the issue of evaluating the pathogenicity of TTNtvs Hinson et al. used 
cardiac microtissues engineered from induced pluripotent stem cells (iPS cells) to assess 
the cellular effects of two A-band TTNtvs and a missense mutation located in the Z-I-
junction. All the cardiac microtissues produced from mutated iPS cells exhibited less than 
half the contractile force than the wild type. (148) The authors also tackled the question of 
I-band TTNtvs found in healthy individuals without the DCM phenotype, and concluded 
that alternative splicing explains this disparity. Roberts et al. reached the same conclusion 
and used the concept of proportion spliced in (PSI) as a measure of this phenomenon. 
They also reported that many exons in the I-band area are symmetric and can be excluded 
by alternative splicing without affecting the overall structure and function of the protein. 
The mutations located in highly expressed exons, such as the constitutively expressed A-
band, are thus likely pathogenic whereas mutations located in areas exhibiting a low PSI 
are more likely tolerated. (109) Similarly, Akinrinade et al. concluded that TTNtvs 
affecting five or more of seven transcripts should be prioritized in variant analysis, (149) 
and that this corresponds to PSI>0.9 considered as high level of expression by Roberts et 
al.  
????????? ???????????????????????????????????????????????????????????????????????????????? ?????????????????????
????????????????????????????????????????????????????????????????????????????????????????????? ???????
?????????????????????????????????????
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?????? ??????????????????
Desmoplakin (DSP) is an important intracellular component of the desmosome anchoring 
cytoplasmic intermediate filaments to the desmosomal plaques. (89, 151) The first 
desmoplakin mutation was reported in 1999 and linked to a dominantly inherited skin 
condition with acral manifestation called striate palmoplantar keratoderma. (152) Then in 
2002 Rampazzo et al. reported a DSP missense mutation c.897C>G, p.(Ser299Arg) 
resulting in the classic ARVC phenotype also with autosomal dominant inheritance 
pattern. They postulated that different DSP mutations might lead to different phenotypes 
with distinct modes of inheritance. (153) In a further phenotyping study of four families 
with different DSP mutations, including the c.897C>G, p.(Ser299Arg) mutation, left 
ventricular involvement was quite common. (154)  
Another recessive DSP mutation has been reported to cause Carvajal syndrome with 
palmoplantar keratoderma, woolly hair and ARVC, although initially the cardiac 
phenotype was described as dilated cardiomyopathy. (89, 155) Autopsy of a deceased 
patient showed biventricular, but right dominant, dilatation, myocyte loss and fibrosis. 
(156) Whittock et al. described two compound heterozygous infants carrying nonsense-
missense DSP mutations with a severe dermatological phenotype with no apparent 
cardiomyopathy. However, the cardiovascular assessment was not thoroughly described in 
the report. (157) The obvious question remains why the phenotype sometimes involves 
only the skin or the heart and on other occasions both. Varying tissue expression of 
different DSP isoforms has been studied and might offer an explanation, but the answer is 
still inconclusive. (158) 
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?? ?? ???????????????
 
The aims of this study were to identify cardiomyopathy-causing genetic variants and to 
describe genotype-phenotype correlations and disease progression in dilated 
cardiomyopathy. Specific aims were  
 
(I) to search for new LMNA mutations among Finnish DCM patients and to describe an 
atypical laminopathy phenotype 
 
(II) to investigate disease progression in LMNA mutation carriers using repeated 
cardiopulmonary exercise testing 
 
(III) to study disease onset, presentation, progression and gender-specific differences in 
LMNA mutation carriers  
 
(IV) to investigate the genetic background of DCM in a representative cohort of DCM 
patients referred to a tertiary hospital using a new comprehensive tool for genetic 
diagnosis 
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?? ??????????????????????
???? ?????????????????????????????????
 
The study group consisted of 133 probands of Finnish origin with dilated cardiomyopathy 
from the university hospitals of Helsinki and Kuopio. Patient recruitment took place 
between 1999 and 2007. Additionally two patients who did not quite fulfil the 
echocardiography criteria used for diagnosing dilated cardiomyopathy presenting with an 
incomplete phenotype including ventricular dilatation and systolic dysfunction were 
included since a genetic cause was suspected.  
All available family members of the four probands with LMNA mutations reported in 
this study were included in the study and underwent genetic testing concerning the 
family’s LMNA mutation and clinical evaluation including echocardiography.  
The control group for the genetic analyses concerning the LMNA mutation ??????????
??????????????in exon 7 consisted of 186 healthy control individuals of Finnish origin. ?
 
???? ??????????????????????????????????
 
The study group consisted of 26 individuals each carrying one of five cardiomyopathy-
causing LMNA variants identified in previous studies. (110, 111)  The mutations and their 
frequencies are listed in Table 2. The patients were identified and recruited from Helsinki 
and Kuopio University Hospitals.
The control group for the spiroergometry testing consisted of 23 individuals without 
known heart disease. The control group was matched for the study group based on age, sex 
and body mass index. Seventeen of the 23 control individuals underwent 
echocardiography.   
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LMNA mutation Asymptomatic 
carriers (n=12) 
Symptomatic 
carriers (n=14) 
c.394G>C, p.(Ala132Pro) 0 3 
c.568C>T, p.(Arg190Trp) 2 2 
c.1493delG, p.(Ala499Leufs*49) 0 1 
c.427T>C, p.(Ser143Pro) 9 6 
c.1085delT, p.(Leu363Trpfs*117) 1 2 
????????? ????????? ????????????????????????????????????????????
???? ???????????????????????????????????
 
The study group consisted of 27 individuals each carrying one of five cardiomyopathy-
causing LMNA mutations identified in previous studies. (110, 111) The study group 
comprised 24 of the LMNA mutation carriers from Study II and three additional LMNA 
mutation carriers. The recruitment and annual follow-up of these patients took place in 
2005-2010. Clinical endpoint data were collected until 31 December 2014.
The control group for clinical endpoints comprised 78 probands with dilated 
cardiomyopathy diagnosed and recruited before 2010. These control DCM patients were 
collected retrospectively from our database excluding patients who have been recruited as 
study patients after possible heart transplant to avoid possible collection bias. An inclusion 
criterion for the control DCM patients was having been tested for cardiomyopathy-causing 
mutations using Os-Seq, a next-generation-sequencing method, as described in Study IV 
(159) to exclude possible LMNA mutation carriers from the control group. 
Concerning ECG findings the LMNA mutation carriers were also compared to an 
available group of 20 healthy controls (13 females, seven males).  
 
???? ??????????????????????????????????
 
The study group consisted of 145 unrelated probands with dilated cardiomyopathy 
recruited between 1999 and 2013 in Helsinki University Hospital.  
Candidate variants obtained by Os-Seq (method described later) were compared to the 
ExAC database containing > 60 000 individuals including the Finnish Sequencing 
Initiative Suomi (SiSu) database. 
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?? ????????
 
???? ???????????????????????????????????????????????
 
The echocardiography criteria used to diagnose dilated cardiomyopathy in studies I-IV 
were left ventricular end-diastolic diameter (LVEDD) > 27 mm/m2 and left ventricular 
ejection fraction (LVEF) < 45% in the absence of abnormal loading conditions such as 
primary valvular disease or hypertensive heart disease. Patients with the dilated 
cardiomyopathy phenotype secondary to another known cause, such as coronary artery 
disease, or sarcoidosis, were excluded from the study. (13, 111) Clinical echocardiography 
data from hospital records were used, and in many instances echocardiography was done 
by a clinical researcher for research purposes.   
 
???? ????????????????????
?????? ?????????????????????????????????????
The criteria used for the diagnosis of DCM were the ones stated in 4.1. All available 
hospital records were used for clinical endpoint data collection. Incidence times of atrial 
fibrillation, non-sustained ventricular tachycardia (NSVT), resuscitation or appropriate 
ICD therapy, i.e. ICD shock or antitachycardia pacing in response to sustained ventricular 
tachycardia or ventricular fibrillation, likely cardiogenic embolism and pacemaker/ICD 
implantations were recorded. NSVT was defined as more than 3 consecutive ventricular 
beats. Due to less regular follow-up of the DCM control group compared to the LMNA 
mutation carrier group NSVT was not recorded in the DCM control group. Due to the 
relatively small size of the LMNA mutation carrier group, a composite endpoint of 
resuscitation, appropriate ICD therapy, death and heart transplantation was used in 
survival analysis.  
 
?????? ?????????????????????????????????
All available hospital records of the probands and their family members were obtained 
from hospitals listed by the study patients at recruitment and analysed in detail. The 
echocardiography criteria stated in 4.1 for the diagnosis of DCM were used. 
Electrocardiograms, anthropometrics, clinical echocardiography data, age at DCM 
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diagnosis, age at death, detection of atrial fibrillation, angiography, pacemaker 
implantation, resuscitation or appropriate ICD events, and transplantation were recorded. 
Familial (dilated) cardiomyopathy was defined as a confirmed family history of any 
cardiomyopathy, including hypertrophic, dilated or arrhythmogenic right ventricular, or 
two or more family members with atrial fibrillation before age 40, or rhythm/conduction 
disturbances necessitating pacemakers in the family. 
 
???? ??????????????????????????????????
 
?????? ??????????????
The genetic analyses were mainly performed in the Diabetes and Heart Disease Research 
Unit at the University of Eastern Finland. Peripheral blood leukocytes were used for DNA 
extraction. Amplification was performed using polymerase chain reaction (PCR). 
Sequencing of the coding regions of the LMNA gene was done using ABIPRISM 310 or 
3100 Genetic analyzer (PE Applied Biosystems, Foster City, CA, USA).  
The genetic analyses concerning desmosomal proteins took place at the University of 
Helsinki. Protein-coding exons and exon-intron junctions of plakophilin-2b (PKP2b) were 
targeted. Amplification was performed using PCR. Sequencing was performed using 
BigDye Terminator v3.1 Cycle Sequencing Kit and ABI 3730xl DNA Analyzer (Applied 
Biosystems, Carlsbad, CA, USA). Additionally the previously known Finnish ARVC-related 
variants were sought using either direct sequencing or restriction enzyme assays. (96, 97) 
The five LMNA mutations and the mutation carriers further phenotyped in studies II 
and III were identified in two previous studies. (110, 111) 
 
?????? ??????????
A targeted sequencing method, OsSeq was used. (122) The gene panel used, Pan 
Cardiomyopathy Panel, Blueprint Genetics v. 1.0, consisted of 51 DCM-related and 50 
candidate genes implicated in other cardiomyopathies. Peripheral blood samples were 
used for DNA extraction. DNA capture and sequencing were performed using the MiSeq 
sequencer. 
The raw data was pre-processed with Trimmomatic in paired-end mode. (160) The 
Burrows-Wheeler Aligner (BWA) (161) was used for mapping the reads to the human 
genome reference sequence (hg19).  The Genome Analysis Toolkit (GATK) (162) version 
3.1-1 was used for genotyping. Variant annotation was done with Ensembl’s Variant Effects 
Prediction (VPE) tool. (163) In silico prediction of missense variants was performed using 
the dBNSFP database. (164) Candidate variants obtained were compared to the ExAC 
(Exome Aggregation Consortium) database containing the exome data of over 60 000 
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individuals including the Finnish SiSu database. Variants were classified by a group of 
clinicians and geneticists into five categories: pathogenic, likely pathogenic, variant of 
unknown significance (VUS), likely benign, or benign. Both likely pathogenic and 
pathogenic variants were considered diagnostic.  
 
???? ? ??????????????????????????????
 
Myocardial samples of two patients in study I carrying the LMNA variant ??????????
????????????? were assayed immunohistochemically for plakoglobin, a desmosomal 
protein. The immunohistochemical analyses were performed in the Neuromuscular 
Research Unit of the University of Tampere. Myocardial sample sections were stained with 
plakoglobin antibody (Sigma-Aldrich, St Louis, MO, USA) in dilution 1:10000 using the 
official protocol of the BenchMark immuno-stainer. For visualization a detection kit 
(UltraView Universal DAB detection kit, Ventana Medical Systems Inc, Tucson, AZ, USA) 
for primary antibodies was used.?
 
???? ????????? ?????????????????????
 
Electron microscopy was performed on an endomyocardial specimen of a patient in study I 
carrying the LMNA variant ?????????? ?????????????. The electron microscopy sample 
preparation took place as follows: 2.5% glutaraldehyde in 0.1M phosphate buffer was used 
at pH 7.4 and at room temperature for 2 hours. Postfixation was performed in 1% osmium 
tetroxide for an hour, followed by dehydration in ethanol and embedding in LX 112. 
Toluidine blue was used for semithin sections, and uranyl acetate and lead citrate for thin 
sections. A Jeol 1400 electron microscope was used to visualize the specimen.?
 
???? ???????????????????????????????????????
 
Parametric linkage analysis to assess co-segregation of the LMNA mutation c.1380G>C, 
p.(Glu460Asp) and cardiac involvement was performed on a pedigree in Study I (see the 
pedigree in Figure 1 of the original publication). An affected-only model was used on 
Merlin software (165) designed for pedigree analysis. The disease and marker allele 
frequencies were set at 1:10,000. Individuals with atrioventricular blocks, arrhythmias, or 
DCM were considered affected. 
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???? ???????????????????????????????????????????????
 
An electrically braked bicycle ergometer was used in the work conducted exercise tests, 
and ECG was monitored continuously.  Blood pressure was measured manually before 
exercise, at each exercise level, and 4 to 6 minutes after exercise. Non-invasive arterial 
oxygen monitoring with two pulse oximeter sensors was used (one in ear lope and another 
in left middle finger). For women a 40 W and for men a 50 W initial workload and 
increments every 3 minutes were used to achieve a maximal exercise level. Reference 
values using corresponding steps were used to compare the results.(166) To ensure the 
maximality of the test a subjective level 17-19/20 on the Borg scale and a respiratory 
quotient > 1,0 from breath gas analysis was required if subjective symptoms did not 
interrupt the test before this. For the respiratory gas-exchange monitoring a tightly 
attached face mask was used and the breathing gases were collected and analysed breath-
by-breath by the equipment described in brief in in Table 3. The key parameters measured 
during spiroergometry are listed in Table 4. For the gas exchange parameters 30 seconds 
mean values were used in calculations. Ventilatory anaerobic threshold was measured at 
the point when the slope change of carbon dioxide production exceeds oxygen 
consumption, ventilation over oxygen consumption (VE/V̇O2) increases in comparison to 
ventilation over CO2 production (VE/V̇CO2), and when there is an increase of partial 
pressure of oxygen (PetO2) compared to carbon dioxide (PetCO2) in expiratory air. (70) 
 
Ergometer 
 
 
 
 
ECG monitoring 
 
 
 
Gas exchange analysers 
 
 
 
Blood pressure measurement 
 
 
Pulse oximeters 
Electrically braked bicycle ergometer 
(Ergoselect ERG Ergometer; Marquette 
Hellige, Marquette Medical Systems, 
Germany), 
 
Continuous ECG monitoring and recording 
(Mason-Likar and CardioSoft version V6.5, 
GE Medical systems, Milwaukee, WI, USA),  
 
Vmax Encore, Sensormedics, Yorba Linda, 
CA, USA, Face mask (Rudolph series 7910, 
Hans Rudolph, Kansas City, MI, USA),  
 
Manual blood pressure measurement (Erka, 
Germany)   
 
Datex-Ohmeda 3900 and Datex-Ohmeda 
3800 (Datex-Ohmeda, Louisville, CO, USA) 
Initial workload and workload increment at 
3-minute intervals 
40W for females, 50 W for males 
Test completion Borg 17-19/20, and RQ > 1.0 
????????? ????????????????????????????????????????????????????????????????????????????????????????????????????
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? ?
 
????????? ???????????????????????????????????
?????? ?????????????????????
The LMNA mutation carriers underwent cardiopulmonary exercise testing, or 
spiroergometry, annually between 2005-2010 one to six times depending on the time of 
recruitment, changes in clinical condition (including two ICD implantations, two heart 
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transplantations and three cases where the clinical condition otherwise progressed) and 
other conditions which prevented the study (including a bone fracture in one study patient 
and pregnancy in another). The study attendance numbers and the reasons for dropout are 
given in Table 5. 
 
 Baseline Control 
visit 1 
Control 
visit 2 
Control 
visit 3 
Control 
visit 4 
Control 
visit 5 
Symptomatic 
carriers 
14 12 10 5 7 4 
Asymptomatic 
carriers 
12 11 11 10 10 6 
????????? ??????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ??????????????????????????????????????
??????????????????????????????????????????????????????????????????????? ???????????
???? ??????????????????????????????????????????????????
Study III contained the analysis of the ECG characteristics of the cohort of 27 LMNA 
mutation carriers, 20 healthy controls and 78 controls with dilated cardiomyopathy. One 
standard 12-lead ECG recording at 50mm/sec speed was used. The ECG assessment was 
performed by an experienced investigator (K.N.) blinded to the clinical data. The criteria 
used in ECG analyses are given in Table 6. 
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1st degree atrioventricular block PR interval >200ms (167) 
P terminal force P wave in lead V1 ≥ -0.4 (168) 
Flat P wave P wave amplitude <1 mm in lead II (169) 
Broad P wave P wave ≥120ms in lead II (169) 
Left ventricular hypertrophy (LVH) Sokolow-Lyon (170) or the Cornell voltage 
duration product criteria (QRS-duration 
(ms) x (RaVL (mm) + SV3 (mm) (+6mm for 
women)) ≥2440) (171, 172) 
Criteria for ST segment depression ≥0.5mm if the pattern was horizontal or 
descending, and ≥1mm if ascending in ≥2 
adjacent leads measured at the J point + 
60ms (173) 
T wave inversion ≥1 mm in ≥ 2 adjacent leads, except for 
leads aVR and V1 (174) 
QRS fragmentation Das criteria (in ≥2 adjacent leads) (175) 
Septal fragmentation Presence of QRS fragmentation in ≥2 septal 
leads (V1-V3) 
Non-specific intraventricular conduction 
block 
QRS ≥120ms not fulfilling criteria for right 
or left bundle branch block 
Septal remodelling At least one of the following in V1-V3: 1) 
pathological Q waves in ≥2 parallel leads, or 
2) QRS fragmentation in ≥2 parallel leads, 
3) poor R wave progression (R wave <3mm) 
in leads V1-V3 accompanied by QRS 
fragmentation, or disorderly distributed R 
wave amplitudes, either RV2>RV3 or 
RV1>RV2 
????????? ????????????????????????????????????????????????????
???? ?????????????????????
 
?????? ?????????
Statistical analyses in Study II were done using SPSS version 20.0 (SPSS Inc, Chicago, IL, 
USA). For the statistical analyses the study group was divided in two, symptomatic and 
asymptomatic LMNA mutation carriers, depending on phenotype. Covariance analysis was 
used to compare the spiroergometry results of the symptomatic and asymptomatic 
mutation carriers to healthy controls. For the spiroergometry parameters concerning 
oxygen uptake, heart rate or working capacity age, gender, weight, height and the use of 
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beta-blockers were included as covariates. For the spiroergometry parameters measuring 
ventilation and echocardiography parameters the covariates used were age, gender, weight 
and height. In the few instances where the parameters were not normally distributed the 
comparisons of the mutation carriers to the healthy controls giving statistically significant 
results were confirmed using the non-parametric Mann-Whitney U test. Paired t-test was 
used to compare the results of the follow-up visits to the baseline visit in both the 
symptomatic and asymptomatic mutation carrier group. Bivariate correlation tests were 
performed between LVEF in echocardiography and some gas exchange variables. Pearson 
correlation was used as the parameters were normally distributed. 
 
?????? ??????????
SPSS version 22.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analyses.  Shapiro-
Wilk test for normality was used to assess the normality of continuous variables. Student’s 
t test was used to analyse continuous variables.  Mann Whitney U test was used if the 
variables were not normally distributed. The Chi-square test or the Fisher exact test was 
used for categorical variables when appropriate. In the ECG analyses the p-values obtained 
were multiplied by two to account for the number of paired-wise comparisons. For survival 
analysis Kaplan-Meier was used. Due to the size of the group studied and the small 
number of events observed compound parameters of different events were used to 
compare outcomes between LMNA mutation carriers and DCM controls. 
 
?????? ?????????
Statistical analyses were performed using R statistical software. Continuous data was 
expressed as mean ±?SD when normally distributed and median?±?interquartile range 
when not. Normality of the data was assessed using the Shapiro-Wilk test. Continuous 
variables were compared using independent samples t test combined with Levene’s test to 
assess the equality of variances if the data were parametric and Mann Whitney U test if the 
data were non-parametric. Differences were considered statistically significant when 
p<0.05 (two-sided p-value was used). Categorical data was expressed as frequencies. 
Comparisons of frequencies were done with either the Chi-square test or the Fisher exact 
test as appropriate.  
 
????????????????????????????
 
All the studies I-IV were approved by the Ethical Committee of the University of Helsinki 
(Decision number for studies I-III: Dnro 322/E5/03, decision number for study IV: Dnro 
307/13/03/01/11) and were in compliance with the Helsinki Declaration. All the study 
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patients have signed informed consent to participate in the study. To justify this project 
the aim was to provide clinically relevant information to the patients and their family 
members. 
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???? ?????????
??????????? ??????????? ????? ????? ????? ????????? ?????
???????? ????????????????????????????????????????????????
???????????????????????
 
?????? ????????????????
From the 135 cardiomyopathy patients studied four LMNA variants considered disease-
causing, c.497G>C p.(Arg166Pro), c.710T>C p.(Phe237Ser), c.1442dupA p.(Tyr481*), and 
c.1380G>C p.(Glu460Asp), were found yielding a prevalence of 3.0% in this cohort. None 
of the variants were present in the 186 healthy controls of Finnish origin. The Arg166Pro 
LMNA variant has been previously described (176) and the other three were novel. None of 
the four variants are present in the reference population database ExAC. 
 
?????? ?????????????????????????
The proband harbouring the c.1380G>C, p.(Glu460Asp) variant first presented at age 48 
with atrioventricular block, which was complete during night time. After pacemaker 
implantation his condition remained stable, apart from intermittent atrial 
flutter/fibrillation, which later became chronic. However, some 2 and a half years later he 
developed New York Heart Association (NYHA) class III symptoms compatible with heart 
failure. In echocardiography LVEDD was 58mm and an LVEF 20%. Beta-blocker, ACE-
inhibitor, digoxin, furosemide, and warfarin medications were started, and he responded 
well to medication. His latest echocardiography findings at age 64 showed a similar 
LVEDD and an LVEF of 42%.  
All in all, the c?????????? ????????????? variant was found in 13 family members, the 
proband included, nine or ten of whom had clinical cardiac findings compatible with 
cardiolaminopathy. Three mutation carriers, aged 17-33 at the time of clinical assessment 
were completely asymptomatic with normal ECG and echocardiography findings. One 34-
year-old female had normal standard ECG and echocardiography findings, but some 
nocturnal unconducted P waves in 24-hour Holter. Three family members (aged 23, 44 
and 53) had only first-degree atrioventricular block in ECG with possible extrasystoles as a 
clinical manifestation compatible with laminopathy. Four mutation carriers had third 
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degree atrioventricular block necessitating a pacemaker, and three of them also atrial 
fibrillation. One 54-year-old mutation carrier had atrial fibrillation.?
The in silico prediction tool PolyPhen-2 gave a benign prediction of the pathogenicity of 
the variant. Using a parametric affected-only model on Merlin software and classifying 
family members with atrioventricular blocks, arrhythmias or dilated cardiomyopathy as 
affected, a logarithm of odds (LOD) score of 2.96 was obtained. The mutation was not 
present in the 150 healthy Finnish controls of a previous study. (110)  
 
?????? ????????????????????????
The proband carrying the previously described c?????????????????????? LMNA mutation 
(176) first presented with atrial fibrillation at age 50. After cardioversion she had first to 
third degree atrioventricular block, non-sustained ventricular tachycardia and short sinus 
pauses, and some months later she received a pacemaker. At age 53 she had a likely 
cardiogenic stroke during an episode of paroxysmal atrial fibrillation. She developed a 
progressive phenotype of dilated cardiomyopathy over the course of several years leading 
to heart transplantation at age 61. Compatible with laminopathy her left ventricle was only 
moderately dilated with an LVEDD of 54mm, corresponding to 29mm/m2, shortly prior to 
transplantation. Additionally, she suffers from a mild progressive distal sensorimotor 
primary axonal polyneuropathy.  ?
The proband’s mother received a pacemaker due to total block at age 57. According to 
hospital records, three aunts or uncles from her mother’s side had cardiac abnormalities. 
There was no available material for genetic testing. The proband’s daughter did not carry 
the c????????? ????????????? mutation and was healthy in clinical assessment including 
electrocardiography and echocardiography at age 35.?
Poly-Phen-2 predicted the c????????? ?????????????? variant to be possibly damaging 
with a score of 0.950 (sensitivity 0.79; specificity 0.95).  
?
?????? ?????????????????????????
The proband carrying the ??????? ????? ???????????? mutation first presented with atrial 
fibrillation at age 41. 10 years later she received a pacemaker due to bradycardia, which 
was shortly upgraded to an ICD due to non-sustained ventricular tachycardia. For several 
years she had a fairly conserved systolic function and only mildly dilated left ventricle, and 
at the time of recruitment to the study she did not fulfil the echocardiography criteria for 
dilated cardiomyopathy. However, her cardiolaminopathy followed a progressive course. 
At age 59 she had some episodes of ventricular tachycardia and ICD therapy, and her 
pacemaker was updated to CRT-D. Some four years later she started having frequent 
episodes of ventricular tachycardia, and developed heart failure. Recently, she had an 
LVEDD of 61mm and an LVEF of 30% in echocardiography, and is currently under 
evaluation for a heart transplant.  
?
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?????? ??????????????????????????
The novel ??????????????????????? mutation was present in six family members and none 
of the studied 186 Finnish controls. Three mutation carriers had the severe phenotype 
affecting in particular the right side of the heart. The three asymptomatic mutation carriers 
were all under 30 years old. There were additionally two obligatory mutation carriers with 
the phenotype. ?
The proband first presented with mild chest pain and dyspnoea at age 43. In 
echocardiography he had a dilated hypokinetic right ventricle, a dilated right atrium, a 
moderately dilated left ventricle with an LVEF of 40%, and a severe tricuspid insufficiency. 
His paroxysmal atrial fibrillation soon became chronic. In coronary angiography he had no 
signs of coronary artery disease. It was first interpreted that the tricuspid insufficiency was 
the main reason for the right ventricular failure, and thus, a mechanical tricuspid valve was 
installed. However, despite the successful valve replacement, the symptoms remained.  
Two years after the initial presentation the heart symptoms progressed, and the left 
ventricular pump function worsened (LVEF was down to 35%). There were still no signs of 
coronary artery disease in coronary angiography. Due to a still deteriorating clinical 
condition he received a heart transplant at age 47. There was fibrotic replacement in the 
histology of the explanted heart especially in the right atrium. 
The proband’s brother presented with atrial fibrillation and heart failure at age 41. He 
had hypokinesia, a mild mitral insufficiency and a significant tricuspid insufficiency in 
echocardiography. After a cardioversion he went to asystole, and after that received a 
pacemaker. In three years the tricuspid insufficiency had progressed to severe stage, and 
all the chambers of the heart were dilated. There were no signs of coronary artery disease 
in coronary angiography. At age 44 he also received a heart transplant. 
The proband’s cousin presented with heart disease at age 44. She had chronic atrial 
fibrillation, and echocardiography showed right ventricular dilatation and failure with a 
normal left ventricular diameter. An endomyocardial biopsy revealed nuclear blebbing; a 
common finding in LMNA mutated cells, and unspecific degenerative changes. She 
developed symptomatic bradycardia 18 months after the initial symptoms, and received a 
pacemaker. The right ventricular failure progressed, but due to follicular lymphoma she 
was not a suitable candidate for a heart transplant. She suffered a cardiogenic stroke at age 
47, and died of heart failure six months later. 
The proband’s mother and aunt, both obligatory carriers of the ????????????????????????
mutation, had similar phenotypes. The proband’s mother had elevated blood pressure 
before the age of 30, received a pacemaker at 43 because of sick sinus syndrome and atrial 
fibrillation. Six months after pacemaker implantation she had a clinically diagnosed 
transient ischemic attack. At 48 she underwent surgery for a ruptured intracranial 
aneurysm. She was diagnosed with heart failure at age 53.  Echocardiography showed a 
significantly dilated right side of the heart, a tricuspid insufficiency and a combined aortic 
valve defect. She had liver cirrhosis due to the right-sided heart failure, and additionally 
developed renal failure. She died at age 56.?
The proband’s aunt presented with sick sinus syndrome and atrioventricular block at 
age 52, and received a pacemaker. She had a mild combined aortic valve defect, mitral 
insufficiency and a massive tricuspid insufficiency in echocardiography. Mitral and 
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tricuspid valvuloplasties were performed when she was 58, but she died of heart failure 
only four months after surgery. The proband has two children who are both carriers of the 
????????????????????????mutation, but at ages 24 and 28 showed no signs of heart disease. 
The proband’s nephew is also a mutation carriers, and at age 22 showed non-specific 
intraventricular conduction defect in ECG, and a slightly reduced performance in 
spiroergometry, but no abnormalities in echocardiography. ?
Due to the family’s ARVC-like phenotype myocardial samples of the proband and his 
brother were analysed using immunohistochemistry for plakoglobin.  The staining pattern 
was normal. 
Additionally, for the same reason, genetic analyses on the proband’s brother and cousin 
were performed.  None of the previously described Finnish ARVC-linked desmosomal 
mutations (PKP2 c.176A>T, p.(Gln59Leu), PKP2 c.184C>A, p.(Gln62Lys), PKP2 
c.1839C>G, p.(Asn613Lys), DSP c.4117A>G, p.(Thr1373Ala) and DSG2 
c.3059_3062delAGAG, p(Glu1020Alafs*18) were found. (96, 97) Neither did the 
sequencing of the protein-coding regions and exon-intron junctions of the plakophilin 2b 
reveal any mutations. 
 
???? ??????????
??????????????? ?????????? ???????? ??? ??? ????? ?????????
??????????
 
Due to the heterogeneity of the phenotype in the study group of 26 LMNA mutation 
carriers the study group was divided into symptomatic and asymptomatic LMNA mutation 
carriers. The symptomatic group comprised 14 mutation carriers with at least one of the 
following clinical manifestations: atrial fibrillation, sustained ventricular tachycardia, 
pacemakers or ICDs, or dilated cardiomyopathy. The remaining 12 mutation carriers 
lacked clinically relevant manifestations of their LMNA mutation.  
Overall the symptomatic mutation carriers showed lower oxygen uptake (statistical 
significance at baseline visit), a non-significantly lower anaerobic threshold and signs of an 
increased ventilatory response during exercise compared to the control group marked by 
higher ventilatory equivalents (V̇EO2 and V̇ECO2), lower ????????? ??? ?????????? ????
?FetCO2) and higher V̇E/V̇CO2 slope values. In echocardiography the symptomatic 
mutation carriers had a lower LVEF than the control group, the difference being 
statistically significant at the baseline and control visits 1 and 3.  
The overall spiroergometry performance and LVEF in echocardiography of the 
asymptomatic carriers compared to the control group was quite similar. However 
V̇E/V̇CO2 slope of the asymptomatic mutation carriers was higher  (statistically significant 
difference from baseline to control visit 2) and FetCO2 was lower (statistically significant 
difference from control visit 1 to 4) than in the control group.  
Figure 3 presents the FetCO2 and V̇E/V̇CO2 slope values of all the LMNA mutation 
carriers and the healthy controls. 
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????????? ??????????????????????????? ???? ??????????????????????????????????????? ?????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????
???? ??????????
???????????????????????????????????????????????????????
??????????????????
 
?????? ????????
Among the 27 LMNA mutation carriers 12 fulfilled the criteria set for DCM (LMNA-
DCM subgroup). The LMNA mutation carriers were younger at the end of the follow-up 
than the DCM controls: the mean age at last follow-up or major endpoint was 48 and 59 y, 
respectively (p<0.001). There was more atrial fibrillation in the LMNA-DCM subgroup 
than in the DCM controls (91.7% vs. 50.0%, p=0.007), but no difference between all the 
LMNA mutation carriers (55.6%) and the DCM controls. LMNA mutation carriers also had 
a first recorded episode of atrial fibrillation at a younger age than the DCM controls (46.9 
vs. 56.9, p=0.003); the finding was essentially the same in the LMNA-DCM subgroup. 
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Similarly, there were more implanted pacemakers in the LMNA-DCM subgroup than in the 
DCM controls (83.3% vs. 47.7%, p=0.020), but again no statistically significant difference 
between all the LMNA mutation carriers (59.3%) and the DCM controls. There was no 
difference in the number of ICDs between all the LMNA-mutation carriers (33.3%) or 
DCM controls (33.3%). The prevalence was a bit higher in the LMNA-DCM subgroup 
(50.0%), but not statistically significantly. Thrombosis was as common among all the 
LMNA-mutation carriers (14.8%) than among the DCM controls (15.4%). Again the 
number was statistically non-significantly higher among the LMNA-DCM subgroup 
(33.3%). Figure 4 shows the endpoint prevalences in all the LMNA mutation carriers, the 
LMNA-DCM subgroup, and the DCM controls. The number of major endpoints (deaths, 
resuscitations, appropriate ICD events, or heart transplants) was lower among all the 
LMNA mutation carriers (25.9%) than the DCM-controls (48.7%). However in Kaplan-
Meier analysis there was no difference in event-free survival of these two groups when the 
definition of major endpoint was the same as above; the median age estimate was 62.8 (CI: 
53.3-72.3) y for LMNA mutation carriers and 68.0 (CI: 64.3-71.7) y for DCM controls (the 
figure presented in the original article). When first incidence of atrial fibrillation, 
pacemaker implantations and thrombosis were included additionally as events LMNA 
mutation carriers had a lower event-free survival age than the DCM controls (median age 
estimates 47.0, CI: 37.4-56.6 for LMNA mutation carriers and 56.9, CI: 53.7-60.1 for DCM 
controls) (Figure 5). NSVT was common among all the LMNA mutation carriers (77.8%). 
By age 50 all LMNA mutation carriers had a clinically relevant manifestation.  
 In Figure 6 the incidence ages of LMNA mutation manifestations in the entire LMNA 
mutation carrier group in study III are given. 
 
????????? ????????????????????????????????????????????????????????????? ????????????????????????????????????????
???????????????? ?????????????????????????????????????????????????????????????????????????????????????
?????????????????????? ????????????????????????????? ??????????????????????????????????????
???????????
??
?? ??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
?? ??
??
??
??
??
??
??
??
? ? ? ? ????????? ? ?? ???????? ? ? ?? ??? ?
????? ???
????????? ???????????????? ????????????????? ????????????
  53 
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  54 
1 
????????? ??????????????????????????? ???????? ????????????????????????????????? ?????????????????????????
????????????
  55 
?????? ????????????????????????????
Figure 7 shows clinical endpoint prevalences in male and female LMNA mutation carriers 
and DCM controls, and Figure 8 the clinical endpoint incidence ages in male and female 
LMNA mutation carriers and DCM controls. Male LMNA mutation carriers had their first 
recorded episode of atrial fibrillation (40.9 vs. 55.4 y, p<0.001), pacemaker implantation 
(41.8 vs. 55.8, p<0.001) and ICD implantation (41.5 vs. 51.2, p=0.007) earlier than male 
DCM controls. Female LMNA mutation carriers differed from the female DCM controls 
only in the number of major endpoints occurred (14.3% vs. 50.0%, p=0.03). 
Looking at the LMNA mutation carriers there was a general tendency for each 
measured event or endpoint to take place at least a decade earlier in males than in females. 
The incidence ages for the different endpoints were: 40.5 and 50.3 y, non-significant, for 
NSVT, 40.9 and 53.7 y, p=0.016 for atrial fibrillation, 41.8 and 58.5 y, p=0.001, for 
pacemaker implantation, 41.5 and 62.7 y, p<0.001, for ICD implantation, 42.2 and 54.1 y, 
p=0.042, for fulfilling the echocardiography criteria for DCM, 48.5 and 56.8 y, non-
significant, for likely cardiogenic thrombosis, and 47.7 and 56.3 y, non-significant, for age 
at major endpoint for males and females, respectively.  
 
????????? ???????????????????????????? ???????????????????? ???????????????????????????????????
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????????????????????????? ????????? ????????????????????????????????????? ????????????????????????
?????????
?????? ???????????????????????????????????????????
The previously known ECG abnormalities typical to laminopathy were also seen in this 
study. Namely, flat P wave and AV blocks were significantly more frequently present in 
LMNA mutation carriers than the DCM controls. Neither was present in any of the 20 
healthy controls used as an additional control group for the ECG analyses. Additionally 
septal remodelling, for the definition see 4.6.7, was present in 81.5% of LMNA mutation 
carriers, only 20.5% of DCM controls and none of the healthy controls. Figure 9 shows the 
prevalence of the abovementioned ECG abnormalities in the three groups. Current or 
previous AV block was used because the presence of an AV block could not be analysed in a 
fairly large proportion of the LMNA mutation carriers or in the DCM controls due to atrial 
fibrillation and ventricular pacemakers. Table 7 shows the sensitivities, specificities, and 
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positive and negative predictive values for ECG septal remodelling in classifying LMNA 
mutation carriers from DCM controls, healthy controls or all the controls.  
  58 
 
 ????? ???? ????
??????? 
????? ???? ????????
??????? 
????? ???? ???? ???
??????????????? 
??????????? ???? ???? ???? 
??????????? ???? ??? ???? 
??? ???? ??? ???? 
??? ???? 80 ???? 
????????? ???????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????? ?????????????????????????????????????????????????????
?????????????????????????????????????????????
 
????????? ????????????????????????????????? ???????????????????????????????????????????????????????????
?????????????????????????????????????? ??????????????????????????????????????????????????????
 
??
??
??
??
??
??
??
??
??
???
??
??
??
? ? ? ?
? ?????? ??? ?
???? ???? ? ?? ? ? ????
???? ? ? ????? ?????? ? ???????? ??? ??? ??? ? ?????
????? ???????????????? ???????????? ????????????????
  59 
???? ???????????
?????????
 
?????? ????????
Sixty-three patients (43.4%) had familial DCM and 82 (56.6%) sporadic DCM. In the 
familial DCM group 69.8% (n=44) and in the sporadic group 76.8% (n=63) were males. 
Males had a larger LVEDD (72 vs. 64mm, p<0.001) and a lower LVEF (23 vs. 28%, 
p=0.003) than females. There were no gender-specific significant differences concerning 
the frequencies of atrial fibrillation, arrhythmias, resuscitation, or implanted pacemakers. 
However, men were younger than women at the time of resuscitation or appropriate ICD 
event (47.6 vs. 65.4, p=0.001). There were no differences in frequencies of atrial 
fibrillation, pacemakers, heart transplants, resuscitations, histological samples 
(=endomyocardial biopsy or a histology report of the explanted heart), or angiography in 
the familial vs. non-familial groups. 
When the pathogenic and likely pathogenic variables were considered disease-causing 
the diagnostic yield was 35.2% (n=51) for the entire group. The diagnostic yield was 
significantly higher for the familial than the sporadic cases (47.6%, n=33 vs. 25.6%, n=21, 
p=0.004).  
 
?????? ????????????
Truncating titin mutations explained 17.2% in the entire study population, 20.6% among 
the familial DCM patients and 14.6% among those with sporadic DCM. Segregation 
analysis was possible in five families. The TTN-mutation co-segregated with the disease in 
all five cases.  
Altogether there were 64 unique rare TTN variants in the cohort present in 71 probands 
(48%). 38 of these variants were missense. 21 TTN variants were truncating; 11 non-sense, 
9 frameshift, and one consensus splice-site variant. Additionally, one truncating variant 
was classified as a VUS due to its commonness and the fact that it affects only one 
transcript.  
62% (13/21) of the truncating TTN mutations were located in the A band region of the 
sarcomere, and 95% (20/21) of them affected all transcripts of the gene.  
  
?????? ???????
LMNA mutations were present in 12 (8.3%) and DSP mutations in 8 (5.5%) probands. Six 
of the probands with DSP mutations had the same novel c.6310delA p.(Thr2104Glnfs*12) 
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variant whereas three of the LMNA mutation carriers had the Finnish founder mutation 
c.427T>C, p.(Ser143Pro). Additional causative variants found were two RBM20 variants, 
one dystrophin (DMD) variant and one telethonin (TCAP) variant.    
 
 
?????? ??????????????????????????????????????????????????????
Table 8 shows clinical characteristics of the probands carrying TTNtvs compared to the 
others probands. No statistically significant differences were seen. Co-segregation was 
possible to analyse in five families (13 individuals) carrying TTNtvs. The penetrance was 
full by age 70 as seen in Figure 10. 
LMNA mutation carriers had a statistically significantly smaller LVEDD and LVEDD 
index than TTN mutation carriers.  They also had more pacemakers than TTN mutation 
carriers and had been resuscitated or had experienced an appropriate ICD shock more 
often than TTN mutation carriers. Atrial fibrillation and pacemakers were more common 
in LMNA mutation carriers than TTN or DSP mutation carriers.  
 
 TTN (n=25) Others (n=120) 
Age at diagnosis 43.4 46.5 
LVEDD 70.1 70.7 
LVEF 23.1 23.5 
Pacemaker 0 8.3 
CRT 4 7.5 
CRT-D 8 15.8 
ICD 20 17.5 
Transplantation 28 30 
Resuscitation 12 20.8 
????????? ?????????????????????????????????????????????????????????????????????????????????
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?????? ????????????????????????????????????????
Cardiomyopathy caused by LMNA mutations is well characterized, the most typical 
manifestations being atrioventricular conduction disturbances, atrial and ventricular 
arrhythmias, and dilated cardiomyopathy often with somewhat modest left ventricular 
dilatation. (22, 139) Study I describes an atypical cardiomyopathy phenotype present in 
five carriers of a novel c.710T>C, p.(Phe237Ser) LMNA variant. The phenotype consists of 
severe cardiomyopathy mainly in the right side of the heart leading to heart 
transplantation in two carriers and death in three. Three carriers did not yet show the 
phenotype characteristics in early adulthood, which is compatible with the age-dependent 
presentation of dilated cardiomyopathy and cardiolaminopathy. (22, 103) The mutation 
carriers did not fulfil the ARVC criteria, (87) however they did not undergo systematic 
assessment to exclude or diagnose ARCV, for instance 24 hour ECG data was available 
from only one mutation carrier and signal averaged ECG from none. Subsequent to the 
publication of study I the ?????????? ????????????? variant was found in another Finnish 
proband with a similar right-predominant cardiomyopathy phenotype diagnosed initially 
at age 44. The patient’s father had died of heart failure before age 50. (T. Heliö, personal 
communication)??
LMNA mutations have also been found in 4% (4/108 patients) of the patients in an 
ARVC cohort reported by Quarta et al. Two mutations, c.214C>T p.(Arg72Cys), and 
c.1145G>T p.(Gly382Val), were novel, and two, c.568C>T p.(Arg190Trp), and c.1930C>T 
p.(Arg644Cys), were previously described. (92) 81 of the patients had a definite and 27 
borderline diagnosis according to the 2010 ARVC criteria. The c.568C>T p.(Arg190Trp) 
mutation has been reported multiple times in DCM patients including a Finnish study of 
DCM patients having undergone heart transplantation. (110, 139, 177, 178) It is also one of 
the mutations present in our studies II and III. The c.1930C>T p.(Arg644Cys), mutation 
has been reported multiple times before, in association with varying laminopathy 
phenotypes including DCM, ARVC, muscular dystrophy, and atypical progeria. (179-183) 
In a study by Mercuri et al. the proband and his mother had a similar phenotype of 
muscular dystrophy and cardiomyopathy, but only the proband was a mutation carrier 
suggesting another cause for the familial disease. (179) In a further study it was found that 
the proband also carried a desmin mutation and his explanted heart showed an abundance 
of desmin accumulation. Additionally the proband’s healthy father was found to be a 
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carrier of the c.1930C>T p.(Arg644Cys) LMNA mutation. This evidence put together 
suggests that the pathogenic mutation in this case was in fact the desmin variant as 
opposed to the c.1930C>T p.(Arg644Cys) variant. In a study by Csoka et al. the proband 
carrying The c.1930C>T p.(Arg644Cys) variant suffered from “atypical progeria” described 
as short stature, thinned skin, generalized wasting and survival to a relatively old age. No 
segregation-analysis was done, but in immunofluorescence microscopy of the mutant 
fibroblast cell line mild nuclear irregularity was seen, less so than in the other mutant 
LMNA cell lines, but more than in a control cell line. (180) Rankin et al. presented nine 
patients carrying the same LMNA variant with varying manifestations compatible with 
laminopathy, such as lipodystrophy, neuropathy, DCM, and muscular dystrophy. However, 
the variant did not show co-segregation with a laminopathy phenotype in any of the 
studied families. (184) In a study of SCD victims the c.1930C>T p.(Arg644Cys) variant was 
found in one victim, but family history was unavailable, thus again co-segregation was not 
shown. (183) Furthermore, the c.1930C>T p.(Arg644Cys) variant is present in ExAC with 
an allele frequency of 0.0016 for non-Finnish Europeans suggesting that the c.1930C>T 
p.(Arg644Cys) is more likely a VUS. (131) The other three LMNA variants reported in 
ARVC patients in the Quarta et al. study are not found in ExAC.  In 2015 Forleo et al. 
reported an LMNA variant c.418_438dup, p.(Leu140Ala146dup) in a large Italian family 
with a varying phenotype of ARVC, DCM, conduction disturbances, arrhythmia and SCD 
co-segregating with the LMNA variant. (185)  
Our study is compatible with the other recent studies cited here, presenting a 
cardiolaminopathy affecting the right side of the heart. While Quarta et al. presented 
probands fulfilling the ARVC criteria, Forleo et al. presented a family with both DCM and 
ARVC phenotypes. (92, 185) The other three mutations presented in study I represent the 
more typical form of cardiolaminopathy. 
 
?????? ????????????????????????????????????????? ??????????????????
In study II individuals carrying DCM-causing LMNA-mutations were studied repeatedly 
using spiroergometry. The study group was heterogenic ranging from asymptomatic 
mutation carriers to individuals with dilated cardiomyopathy. With increasing genetic 
testing of cardiomyopathy patients and their family members the number of asymptomatic 
individuals known to carry cardiomyopathy-causing mutations also increases.  The clinical 
follow-up protocols of these individuals vary, and there are no detailed guidelines for this 
purpose.  
To address the issue of asymptomatic individuals in particular the study group was 
divided in symptomatic and asymptomatic mutation carriers. The symptomatic mutation 
carrier group consisted of patients with clinically significant arrhythmias, pacemakers or 
with dilated cardiomyopathy. Consistent with this they showed a lower maximal working 
capacity, maximal oxygen uptake and FetCO2, and an increased slope of 
ventilation/carbon dioxide exhaled, or VE/VCO2 slope, namely, changes seen typically in 
heart failure patients. (71, 77, 83) The mechanisms underlying inefficient ventilation in 
heart failure patients are considered multifactorial including a lowered anaerobic 
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threshold, altered breathing patterns, ventilation-perfusion mismatching caused by 
reduced perfusion in areas with good ventilation, increased sensitivity of chemoreceptors 
to metabolic changes and abnormalities in the ergoreflex. (76, 186, 187) 
The overall performance of the asymptomatic mutation-carriers was comparable to the 
control group. However, also the asymptomatic mutation carriers had a higher VE/VCO2 
slope level and a lower FetCO2 level than the controls suggesting inefficient ventilation 
during incremental exercise. (76, 85) Due to the generally good performance in 
spiroergometry of the asymptomatic mutation carriers, the mechanisms underlying the 
abnormalities seen are not obvious. Possible mechanisms might include changes in 
chemosensitivity or ventilation-perfusion coupling. (187) These results suggest that 
inefficient ventilation during exercise might be a sign of evolving cardiomyopathy in 
LMNA mutation carriers who are considered still unaffected by the mutation by other 
means of clinical assessment.  
 
?????? ??????????????????????????????????????????
There was a consistent difference in the ages of onset of clinical manifestations in men and 
women in study III, namely men presented with the various clinical cardiomyopathy or 
laminopathy manifestations at a younger age than women. In the landmark Olmsted 
county study from 1989 both the incidence and prevalence of idiopathic DCM was 
threefold in men compared to women. (16) Other studies have also found a difference, 
albeit a smaller one, in the prevalence of DCM between men and women. (41, 188, 189) 
Furthermore women are far less likely to undergo heart transplantation than men; 
between 2005 and 2010 women comprised 23% of heart transplant recipients. (190) Also 
the outcome in heart failure is more favorable in women as shown by a follow-up study of 
the Framingham Heart Study reporting 5-year survival rates of 25% for men and 38% for 
women after congestive heart failure diagnosis. (191) 
Given these well-established gender-specific differences in disease prevalence and 
outcome in the wider heart failure population it is not surprising that similar differences 
should be seen also in LMNA mutation carriers. In a study by VanRijsingen et al. gender-
specific differences were also reported; male LMNA mutation carriers were more likely to 
have LVEF?45% than women. Men also had a higher prevalence of end-stage heart failure 
and malignant arrhythmias and a higher mortality than women. However, the prevalence 
of AV block, atrial tachyarrhythmia, and NSVT did not differ between the sexes. (192)  
The mechanisms underlying these clinical differences between genders are likely 
multifactorial. Possible biological mechanisms include the effects of sex hormones on 
cardiomyocytes. Estradiol acts as a cardioprotective agent by preventing cardiomyocyte 
apoptosis, cardiac hypertrophy and fibrosis. (193) A homozygous LMNA c.665A>C, 
p.(His222Pro) knock-in mouse-model has also been studied giving some mechanistic 
evidence of the effects of androgens on the development of the cardiomyopathy phenotype. 
(194) However, the applicability of these results to humans and cardiomyopathy inherited 
in an autosomal dominant pattern can be questioned. Behavioral patterns can also play a 
role; in a large American study women were 50% more likely to follow national 
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recommendations of smoking abstinence, physical activity and fruit and vegetable 
consumption. (195) Men also consume more alcohol than women globally and in Finland. 
(196, 197) Although it is still debated whether excessive alcohol consumption alone can 
cause the dilated cardiomyopathy phenotype or if a genetic vulnerability is needed, it is 
well accepted that there is a link between excessive alcohol use and the dilated 
cardiomyopathy phenotype. (198) 
 
?????? ??????????????????????????????????????
The study patients in study III were under rigorous follow-up. Possibly due to this we 
found an unprecedentedly high prevalence of NSVT among LMNA mutation carriers. 
Sudden death is quite common in LMNA mutation carriers and it has been speculated that 
lethal tachyarrhythmia is the likeliest mechanism as sudden death was as common among 
those with pacemakers as those without in a meta-analysis of LMNA mutation carriers. 
(22) This does not mean, however, that the risk for malignant ventricular arrhythmia is the 
same for all LMNA mutation carriers. Another study tackling malignant ventricular 
arrhythmia in LMNA mutation carriers reported that reduced ejection fraction, male 
gender, non-missense mutations, and NSVT were independent risk factors, and malignant 
ventricular arrhythmias occurred in those with at least two risk factors. (68) The same 
study reported NSVT in 37% of LMNA mutation carriers. Our markedly higher number of 
NSVT suggests that with repeated monitoring most LMNA mutation carriers have at least 
one of these risk factors.  
 
?????? ???????????????????
Study III included 27 individuals 24 of whom were also study patients in study II. Of the 12 
individuals defined as asymptomatic in study II 10 (83%) had septal remodeling in study 
III. Likewise, of the 12 individuals defined as symptomatic in study II 10 (83%) had septal 
remodeling in study III. This is to say that septal remodeling in ECG was very common 
among all LMNA mutation carriers including those appearing asymptomatic in clinical 
assessment. Given that also late gadolinium enhancement (LGE) seen in CMR known to 
detect cardiac scarring appears to localize in the septum (199, 200), it seems feasible that 
septal remodeling is a sensitive indicator of scarring, and furthermore, that LMNA 
mutation carriers appear to have myocardial scarring in the septum. In a study presenting 
a large kindred carrying a cardiomyopathy-causing LMNA mutation Raman and colleagues 
also showed LGE localizing in the basal septum. Furthermore, scarring was seen in the 
hearts of deceased relatives in autopsy. (200)  
The European Society of Cardiology Working Group on Myocardial and Pericardial 
Diseases recommends continuous clinical follow-up of asymptomatic carriers of 
cardiomyopathy-causing mutations. (103) With limited resources and an increasing 
number of asymptomatic mutation carriers this is a burdensome task for the health-care 
system. In the case of asymptomatic LMNA-mutation carriers the standard ECG might be 
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a useful tool for allocating resources. For instance those with yet normal ECG could be 
monitored less vigorously and those showing signs of cardiolaminopathy, such as septal 
remodeling in ECG, could undergo more frequent assessment.  However, to assess the 
specificity and clinical usefulness of ECG septal remodeling, studies including patients 
with other cardiac diseases, such as ischemic and inflammatory heart disease, should be 
performed. 
 
 
???? ?????????
 
In Finn-DCM a targeted sequencing panel using OS-Seq technology and covering 101 genes 
associated with cardiomyopathy was used to study 145 Finnish DCM patients. Although 
the variant classification criteria for pathogenicity were strict, more than 1 in three of all 
DCM patients (35%) and nearly half of those with familial disease (48%) received a genetic 
diagnosis showing the utility of such an approach in the study of genetic DCM. Pugh et al. 
using a smaller panel of up to 46 genes, and similar criteria for pathogenicity found a 
diagnostic yield of 27-37% with the lower number containing only pathogenic or likely 
pathogenic variants and the higher additionally those variants of unknown significance 
whose assessment favored pathogenicity. (101) Haas et al. studied a large cohort of 639 
DCM patients with a panel containing 84 genes. They reported a higher diagnostic yield of 
73% with 38% of the patients carrying two or more mutations. The variant classification 
system they used, however, was very different from ours, or the one used by Pugh at al. As 
a basis for classification they considered variants listed as cardiomyopathy or 
channelopathy variants in Human Gene Mutation Database (HGMD) pathogenic. (106) 
This can be criticized, however, as HGMD contains variants previously considered 
pathogenic but with the emergence of reference databases now known to be likely 
polymorphisms. (201) As an additional check-up Haas et al. excluded variants present in 
ESP (Exome Sequencing Project), containing the genomes of 6500 individuals, with an 
allele frequency greater than 1%. (106) Suitable cutoff values for allele frequencies when 
assessing pathogenicity are not straightforward to define, but significantly lower values, for 
instance 0,04%, have been proposed for dilated cardiomyopathy. (202) The possibility 
remains, of course, that some of the variants considered possibly pathogenic using looser 
criteria for pathogenicity are in fact modifying variants. An interesting study using exome 
sequencing to study an Italian family with severe DCM found an LMNA c.656A>C, 
p.(Lys219Thr) variant, previously reported to cause DCM (181), in all affected patients and 
additionally a TTN missense variant c.14563C>T, p.(Leu4855Phe) in five individuals. (181, 
203) Those individuals carrying both the LMNA and the TTN variant had a more severe 
clinical phenotype than those LMNA variant carriers without the TTN variant. 
Furthermore the histology of the cardiac tissue of the double heterozygotes was more 
disturbed than the histology of the individuals carrying only the LMNA variant.  
  67 
The novel DSP variant c.6310delA p.(Thr2104Glnfs*12) found in six probands who 
were not apparently related, as confirmed by a genealogy search spanning over several 
centuries, is present in ExAC in four individuals of European ancestry, two Finnish 
individuals and two non-Finnish Europeans.  
The Finn-DCM study comprised of DCM patients predominantly from the Southern 
part of Finland. However, as heart transplantations are only performed in Helsinki, 
patients from all over the country were included. It is likely that the results of Finn-DCM 
are somewhat representative of the entire country. However, it should be accounted that 
recruitment took place in a tertiary centre, which likely biases the patient material towards 
more severe phenotypes. Since the genetic etiology of DCM is varied, local differences 
between studies similar to Finn-DCM performed elsewhere are bound to exist. The DSP 
variant c.6310delA p.(Thr2104Glnfs*12) is a good example of this; the prevalence of 
pathogenic or likely pathogenic DSP variants was unprecedentedly high in Finn-DCM, 
5.5% altogether and 4.1% for the c.6310delA p.(Thr2104Glnfs*12) variant. This is to say the 
high prevalence was mainly due to one variant, a likely Finnish founder mutation. 
Previously, Elliot et al. reported a prevalence of 2%, (94) and Pugh et al. a prevalence of 
2.4% for pathogenic DSP variants in DCM. (101)  
?????? ????
Study IV confirmed the significance of truncating titin variants as the most significant 
known cause for DCM. Of the 21 truncating titin variants considered pathogenic in the 
study all but one affected all transcripts. This is in line with the observations made in other 
studies finding that clinically significant variants affect highly expressed parts of the TTN 
gene, most often the constitutively expressed A-band. (101, 108, 109)   
The prevalence of TTNtvs was 20.6% for probands with familial disease, 14.6% for 
sporadic cases, and 17.2% for the entire study population. In the first TTN report by 
Herman et al. the prevalence of TTNtvs was 25% for familial disease and 18% for sporadic 
disease. The definition for familial disease they used, family history of DCM in a first 
degree relative, was tighter than ours. (108) In the study by Haas et al. the prevalence of 
TTNtvs was 19% in familial and 11% in sporadic DCM. The definition for familial disease 
used was DCM or sudden cardiac death before age 35 in the family. (106) Roberts et al. 
found the prevalence of TTNtvs to be 20% among end-stage and 13% among unselected 
DCM patients. (109) And finally, Pugh et al. reported a prevalence of 14% for TTNtvs in a 
referral genetics laboratory population. (101) The numbers reported in the first TTN study 
are higher than the ensuing ones including ours, which can be explained by the looser 
variant classification criteria used in the Herman et al. study. The initial TTN report also 
raised questions about the relevance of TTNtvs in the general population and the 
distinction between clinically relevant and irrelevant TTNtvs. Following studies have come 
to the conclusion that causative TTNtvs are localized in highly expressed exons whereas 
variants residing in areas exhibiting abundant alternative splicing are less likely to cause 
cardiomyopathy. (109, 149) However, analyzing variants of TTN is still far from simple. A 
recent study presented a computational model for the assessment of pathogenicity of 
TTNtvs taking in account the disruption of an internal TTN promoter, named cronos, and 
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the localization of the variant in the most C terminal part of the gene, in addition to the 
level of expression, or PSI (proportion spliced in). (204) If variant analysis of TTNtvs is 
somewhat complex, the assessment of TTN missense variants is even more so. In study IV 
TTN missense variants were considered at most variants of unknown significance, which is 
the same approach others have used. (101, 108) Since study IV a TTN c.14563C>T, 
p.(Leu4855Phe) variant has been reported as a possible disease-modifying agent making 
cardiolaminopathy more severe as described above. (203) A recent study using whole 
genome sequencing and linkage analysis also reported a TTN missense variant c.533C>A, 
p.(Ala178Asp) as the only plausible causative variant for a combined phenotype of LVNC 
and DCM with an autosomal dominant inheritance pattern in a family with nine affected 
individuals in three generations. Additionally to co-segregation with disease functional 
evidence including reduced binding of the mutant titin to TCAP was seen. (205) The 
largest study of TTN missense variants in DCM to date found missense variants to be very 
common and although preliminary assessment suggested pathogenicity, co-segregation 
with disease was often not seen. They reported, however, four families with TTN missense 
mutations they considered causative showing co-segregation with disease. They concluded 
that TTN missense variants should not be considered disease-causing without careful 
assessment including co-segregation with disease. (206) 
 
?????? ????????????????????????????????
Comparison of clinical characteristics of the probands carrying TTNtvs compared to the 
other probands showed no statistically significant or clinically relevant differences. Thus, 
TTNtv carriers do not seem to form a phenotypically distinct group differing from other 
DCM patients like LMNA mutation carriers do. Similarly, in the first large TTN paper by 
Herman et al. there were no distinct clinical characteristics seen. (108) 
In line with previous studies LMNA mutation carriers in study IV had a distinct 
phenotype characterized by a somewhat small left ventricular size, atrial fibrillation, 
pacemakers and a high incidence of resuscitation or appropriate ICD shock. (15, 22, 139)  
Statistically significant differences were seen comparing the phenotype of the carriers 
of causative TTNtvs compared to the carriers of LMNA mutations regarding left 
ventricular size, pacemaker implantations, atrial fibrillation, resuscitation or appropriate 
ICD shock. Similar differences in left ventricular diameter, atrial fibrillation, presence of 
pacemakers, and having undergone treatment for malignant ventricular arrhythmia could 
be seen when comparing LMNA mutation carriers to DSP mutation carriers and other 
mutation carriers, but due to smaller group sizes only some differences reached statistical 
significance. 
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Studies I-III aimed to deepen the understanding of cardiomyopathy caused by LMNA 
mutations. The main finding in study I was the description of an unusual 
cardiolaminopathy phenotype affecting particularly the right side of the heart. The 
phenotype resembled arrhythmogenic right ventricular cardiomyopathy but did not fulfil 
the ARVC criteria in retrospect. However, ARVC was not extensively sought in the study 
patients, and for example, signal-averaged ECG was not available from any of the study 
patients, and 24 hour ECG was available from only a single patient. It is therefore possible 
that a more extensive workup for the diagnosis of ARVC might have changed this 
interpretation.  
Studies II-III were based on rigorous follow-up of a group of LMNA mutation carriers. 
In study II a weakness concerning the control group was that they were studied only once. 
Another limitation was dropout in the study patient group, which limited the statistical 
analysis in the assessment of disease progression. Spiroergometry is a reproducible 
method to measure cardiorespiratory fitness, (69) although some variation between tests 
of even the same individuals at short intervals has been reported. (207) Spiroergometry 
has also been proven useful in estimating prognosis in heart failure. (77, 82, 83) Recently, 
the ability of spiroergometry as a prognostic tool in the idiopathic DCM population has 
also been shown. (84) While the possible variation in the reproducibility in the 
spiroergometry method is also a limitation in this study it is unlikely to overestimate the 
main findings.  
The repeated examinations were a strength of both studies II and III and lead to the 
finding in study III of an unprecedentedly high prevalence of NSVT in LMNA mutation 
carriers. An obvious weakness of study III was the number of participants limiting the 
number of events during the follow-up. Another limitation was the less frequent follow-up 
of the DCM patients used as controls. A strength of the control group was that they were all 
genotyped using the Pan Cardiomyopathy test panel of study IV. Therefore it is certain that 
there were no LMNA mutation carriers in the DCM control group. In study III ECG septal 
remodelling was introduced as a readily available tool for distinguishing LMNA mutation 
carriers from other cardiomyopathy patients. To establish the clinical usefulness of ECG 
septal remodelling it should be studied in other groups of cardiac patients as other 
conditions affecting the septum might present with the same ECG pattern.  
The study group in study IV was fairly large and well phenotyped. The technology used 
allowed for the sequencing of all genes previously associated with cardiomyopathies. Even 
with strict criteria for pathogenic variants the diagnostic yield was high. However, many 
patients even with known familial disease were still left without genetic diagnosis. As in 
other studies using large gene panels based on next generation sequencing methods many 
variants of unknown significance were found also in this study. Some of them will likely be 
reassessed later as pathogenic variants with more segregation data, which will increase the 
diagnostic yield.  
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All the index patients of this project were recruited in a tertiary centre. This should be 
taken in account when assessing whether the results apply to the broader DCM population, 
as the study patients comprise more severe cases, such as heart transplant recipients. A 
common issue in the study of genetic disease is the availability of segregation data. In this 
project family segregation data was available to analyse in many cases. However, at times 
the availability of family members to phenotype and genotype limited the possibility of 
discovering new causative variants. An aim of this thesis was to find clinically relevant 
genotype-phenotype correlations, and indeed some were found. A problem with this 
specific aim is the number of genes associated to DCM emphasizing the need of 
significantly larger sample sizes, international studies, and sharing of data, to identify 
more genotype-phenotype correlations.  
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Dilated cardiomyopathy is a substantial cause of morbidity and mortality. The possible 
genetic etiology is still often not considered, although, as study IV shows, using currently 
available genetic diagnostics up to a half of patients with familial disease and one in four of 
those without a family history of DCM receive a genetic diagnosis. Study IV also re-
confirmed the role of truncating titin mutations as the most important genetic defect 
causing DCM. Additionally study IV illustrated the usefulness of targeted panels when 
studying the genetic etiology of DCM. With the use of large panels rare variants are found 
in practically all individuals. The only logical approach to variant classification in this 
setting is the use of strict criteria for pathogenicity. The logic behind the classification 
criteria has not changed from the times when single genes were sequenced individually. 
Co-segregation of the variant in question with disease remains the single most important 
evidence of pathogenicity requiring thorough clinical phenotyping of genetic defects. Thus, 
the phenotyping of cardiomyopathy-causing genetic defects is as important as ever, 
although sometimes this appears to be forgotten due to the excitement over technological 
advancements made in the genotyping front.  
A consequence for both strict criteria used in variant classification and the increased 
testing itself is a rising number of DCM patients known to carry variants of unknown 
significance. An important clinical concept concerning variants of unknown significance is 
that they should be considered temporary. With further information gathered from family 
members, other laboratories etc. a VUS should, in time, become a known pathological or 
benign variant.  A significant recent improvement to variant classification is the 
publication of population reference databases, the largest of which is gnomAD. Many 
variants previously considered disease-causing have been proven common variants after 
the population databases became available, increasing the accuracy of variant 
classification. However, many populations are still underrepresented in population 
databases, which remains an obvious limitation to their usefulness. 
This thesis also broadened the known clinical spectrum of cardiolaminopathy, cardiac 
disease caused by LMNA mutations. In Study I a severe right predominant phenotype with 
overlapping characteristics of DCM and ARVC was presented in one family.  Study II 
described the spiroergometry results of 26 LMNA mutation carriers. The mutation carriers 
with a cardiolaminopathy phenotype showed results typical to heart failure patients. The 
yet healthy mutation carriers, on the other hand, had an overall performance similar to the 
healthy controls, but also showed milder signs of inefficient exercise ventilation suggesting 
that increased ventilation during exercise might be an early sign of symptomatic 
cardiolaminopathy.  Study III described clinical follow-up data from 27 LMNA mutation 
carriers. LMNA mutation carriers presented with atrial fibrillation at a younger age than 
DCM patients, however no difference in event-free survival concerning major event was 
seen between LMNA mutation carriers and DCM controls. Male mutation carriers 
presented with clinical signs of cardiolaminopathy significantly earlier than female 
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mutation carriers. In Study III a new ECG concept, ECG septal remodeling, typical to 
LMNA mutation carriers was also introduced. The high prevalence of ECG septal 
remodeling in LMNA mutation carriers suggests that localized septal fibrosis is common in 
this group.  
Overall this thesis added to the knowledge of genetic DCM, and gave insight into the 
clinical features of cardiolaminopathty.  
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